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CHAPTER I 
 
INTRODUCTION 
 
Atherosclerosis 
 Atherosclerosis is a chronic inflammatory disease characterized by 
dyslipidemia and accumulation of lipids in the arterial intima, with activation of 
both innate and adaptive immunity. Reciprocally, dyslipidemia associated with 
atherosclerosis can perturb normal immune function. Natural killer T (NKT) cells 
are a specialized group of immune cells that share characteristics with both 
conventional T cells and natural killer cells. However, unlike these cells, NKT 
cells recognize glycolipid antigens and produce both pro- and anti-inflammatory 
cytokines upon activation. Because of these unique characteristics, NKT cells 
have recently been ascribed a role in the regulation of immunity and 
inflammation, including cardiovascular disease. In addition, NKT cells represent a 
bridge between dyslipidemia and immune regulation. This chapter summarizes 
the current knowledge of NKT cells and discusses the interplay between 
dyslipidemia and the normal functions of NKT cells and how this might modulate 
inflammation and atherosclerosis. 
 Over the past 2 decades, atherosclerosis has gained recognition as an 
immune-mediated process. Many investigators have elegantly demonstrated that 
not only does cholesterol homeostasis play a role in the pathogenesis of 
atherosclerosis, but that innate and adaptive immunity are important in this 
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disease. Atherosclerosis is modulated by infection (1), immunodeficiency (2) and 
autoimmunity (3).  Perhaps one of the most interesting recent discoveries is that 
circulating lipids and immunity are closely linked and have a great deal of 
influence on each other. For example, it has been demonstrated that 
apolipoproteins, such as apoliprotein (apo)E and apo-AI, i.e. molecules that have 
extensively been studied for their role in lipoprotein metabolism and clearance, 
also have important roles in the development of normal immune responses and 
inhibiting inflammation (4, 5). Conversely, it has been shown that modified 
lipoproteins, such as oxidized low-density lipoprotein (oxLDL), can have 
detrimental effects on inflammation by promoting chemotaxis and cytokine 
secretion by macrophages (6). In fact, oxLDL is one of the most prevalent 
antigens associated with atherosclerosis eliciting specific responses from both B 
and T cells. Almost every aspect of immunity, including apoptosis and efficient 
clearance of apoptotic cells by macrophages, has been highlighted as either 
being protective or pathogenic in the atherosclerotic process. In this chapter, we 
will highlight the importance of an interesting member of the innate immune 
system that shares qualities with cells of both innate and adaptive immune 
responses: natural killer T (NKT) cells. As detailed in the following sections, NKT 
cells are unique effector cells that share identity with traditional natural killer (NK) 
cells and classical T cells (Figure 1). Numerous investigators have demonstrated 
regulatory roles of NKT cells and have found that, although few in number, their 
presence and responses can have a catalytic impact on disease progression. 
Their importance in atherosclerosis was emphasized in 2004, when three studies 
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were published demonstrating that activation of NKT cells by specific ligand 
resulted in enhanced aortic lesion formation (7-9). 
 
 
 
 
 
Atherosclerosis and Immunity 
 Atherosclerosis is a disease involving many cellular processes, and has 
long been associated with hypercholesterolemia. A growing body of evidence 
 
 
Figure 1. iNKT cell receptor expression in comparison to NK cells and conventional 
CD4
+
 and CD8
+
 T cells. iNKT cells express surface receptors similar to conventional T cells 
(TCR), as well as NK cells (Ly49 and NKR-P1); however, unlike conventional T cells which are 
activated by peptide antigen presented by MHC molecules, iNKT cells recognize glycolipid 
antigen in the context of CD1d molecules on antigen presenting cells. 
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also supports the role of inflammation and immunity in the pathogenesis of 
atherosclerosis. Studies in CVD have suggested both anti- and pro-atherogenic 
roles for immunity. In general, it has been demonstrated that macrophages and T 
cells make up the largest percentage of immune cells present in the 
atherosclerotic plaque and they appear to contribute to the inflammatory process 
by producing cytokines that attract smooth muscle cells and other lymphocytes, 
and compromise plaque stability (10). CD4+ T cells reactive against oxLDL can 
be isolated from human atherosclerotic lesions (11), and studies in T-cell-
deficient mice have demonstrated a pro-atherogenic role for conventional CD4+ T 
cells. Conversely, CD4+CD25+ regulatory T cells have been shown to protect 
against atherosclerosis (12, 13). 
 Although it was thought that B cells were present in few numbers in 
lesions,  Galkina et al. (14) recently demonstrated that B cells are a significant 
population in both normal and atherosclerotic mouse aortic adventitia. The 
effects of B cells and the antibodies they produce seem to depend on their 
antigen specificity. For example, although titers of oxLDL antibodies are shown to 
correlate directly with severity of disease and are often used as markers of CVD 
risk (15-18), antibodies generated against modified phospholipid (such as 
phosphorylcholine found in oxLDL and apoptotic cells) have been shown to be 
protective (19-22). In fact, immunization of atherosclerosis-susceptible rabbits 
and mice with oxLDL and malondialdehyde (MDA)-LDL results in protection 
against atherosclerosis (22, 23), perhaps via a strong Th2 (anti-inflammatory) 
polarization which seems to rely heavily on IL-5-mediated stimulation of B-1 B 
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cells (20). Conversely, antibodies against 2 -glycoprotein I (2GPI; identified in 
both humans suffering from CVD and in animal models of atherosclerosis (24-28) 
are thought to promote atherosclerosis (29, 30), and immunization of animals 
with HSP-60/65 results in increased atherosclerosis (30-32) . Finally, we have 
shown that specific deletion of B cells in LDLr–/– mice results in enhanced 
atherosclerosis compared to control animals (33). Therefore, it is possible that 
the „quality‟ of the antibody response (i.e. isotype or antigen specificity) may 
influence the atherosclerosis outcome. For more in depth discussion regarding 
adaptive immunity and atherosclerosis see recent reviews on this topic (34, 35). 
 
Innate Immunity and Atherosclerosis 
 It is no secret that innate immunity plays a major role in the atherosclerotic 
process. Macrophages, NK cells, mast cells and dendritic cells have all been 
studied and shown to play a role in plaque progression (35, 36). Macrophages 
are the initial and primary cell type that make up lesions both in humans and 
mice. Numerous studies have focused on the role of macrophages in CVD from 
the aspect of cells important for cholesterol homeostasis and scavenging 
modified lipoproteins and apoptotic cells (37) to their role as mediators of basic 
inflammatory responses. More recent studies have demonstrated that 
macrophages have a unique ability to regulate inflammation in atherosclerosis 
via the expression of Toll-like receptors (TLRs). These receptors, specifically 
TLR-4 (38), TLR-2 (39) and most recently TLR-9 (40), have been shown to play 
integral roles in the development of atherogenic plaques. Mice that are deficient 
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in MyD-88, a shared adapter molecule for TLR-4, TLR-2 and TLR-9, have been 
shown to have decreased atherosclerosis on the apoE–/– and LDLr–/– background 
(38). These studies demonstrated that receptors and molecules once thought to 
only function in immunity against infection have specific roles in the atherogenic 
process. This further emphasizes that atherosclerosis is more than simply a 
disease associated with lipid metabolism and that the intricate interplay between 
immunity, inflammation and dyslipidemia is a significant area of further 
investigation. 
 
Invariant NKT Cells 
 In addition to the more mainstream members of the innate and acquired 
immune system, recent studies have highlighted the role of a less traditional cell 
type, NKT cells, and their role in chronic inflammatory diseases. NKT cells are a 
unique subset of T lymphocytes that share surface receptors with both 
conventional T cells (TCR and CD4) and natural killer (NK) cells (NK1.1 and 
Ly49) and are found in both humans and mice. NKT cells are abundant in the 
liver and most lymphoid tissues, and type I NKT cells, or invariant NKT (iNKT) 
cells, have a restricted T-cell receptor expression (V14-J18/V8 in mice and 
24-J18/V11 in humans) (41). However, unlike conventional T cells which 
recognize peptide antigens presented by major histocompatibility complex 
(MHC) I or MHC II molecules, iNKT cells recognize glycolipid antigen presented 
by the non-classical antigen presenting molecule CD1d on antigen-presenting 
cells (APCs). Upon activation, iNKT cells rapidly secrete large amounts of anti-
7 
 
inflammatory cytokines such as IL-4, IL-10 and IL-13, and pro-inflammatory 
cytokines such as IFN-, which allows for a wide range of regulatory potential 
(42). Activated iNKT cells can also promote dendritic cell maturation and 
monocyte activation by signaling through CD1d (43), and are capable of inducing 
tolerance by communicating with regulatory T cells (44). In addition to displaying 
immune-regulating properties, iNKT cells have been implicated in a variety of 
disease conditions, thus modulation of the functions of these cells may lead to 
potential therapies. For example, studies involving autoimmune diseases 
(highlighted below) have shown that iNKT cells suppress inflammation (45-47). 
iNKT cells have also been shown to increase anti-tumor immunity (48) and 
protect against infections (49) . In contrast, our laboratory (7) and others (8, 9) 
have demonstrated that iNKT cells are pro-atherogenic in both apoE–/– and LDLr–
/– mice, as well as C57BL/6 mice on a high-fat diet. 
 Although few physiological ligand(s) are known, iNKT cells strongly 
respond to and are specifically activated by -galactosylceramide (-GalCer), a 
glycosphingolipid originally isolated from a marine sponge (Agelas mauritanus). 
First identified for its anti-metastatic properties, -GalCer specifically binds to 
CD1d on APCs and selectively activates iNKT cells (50). Activation of iNKT cells 
by -GalCer (synthetic homologue KRN7000) in vivo has been shown to 
suppress inflammation in autoimmune diseases such as type-1 diabetes in mice 
(51); however it has also been shown to exacerbate atherosclerosis (7–9). iNKT 
cells are also activated by other „natural‟ glycolipid ligands, albeit much less 
effectively. For example, several bacterial glycolipids have been shown to 
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activate iNKT cells and may possibly play a role in clearing of infections by iNKT 
cells. Among these are -galactosyldiacylglycerols expressed by Gram-negative, 
LPS-negative Borrelia burgdorferi and -galacturonosylceramide and -
glucuronosylceramide derived from Gram-negative, LPS-negative Sphingomonas 
(52). 
 
iNKT Cell Ontogeny 
 iNKT cells undergo thymic development similar to conventional T cells, 
however they diverge during the double-positive thymocyte stage of development 
(53). In contrast to the selection of conventional T cells by peptide antigens 
presented by MHC molecules, iNKT cell selection requires glycolipid antigen 
presented by CD1d on double-positive cortical thymocytes (54). Once positively 
selected, iNKT cells undergo expansion within the thymus. Most iNKT cells leave 
the thymus as immature (NK1.1–) cells and further mature in the periphery (55, 
56), however, recent studies have shown that a smaller portion of mature iNKT 
cells remain NK1.1– in peripheral tissues and are functionally distinct from the 
NK1.1+ population (57). Mature iNKT cells have the capability to rapidly produce 
large amounts of cytokines upon activation. Although a variety of lipid antigens 
have been shown to activate iNKT cells, each of these molecules must be 
presented to iNKT cells by CD1d. CD1d is an MHC class I-like molecule 
constitutively expressed by APCs, such as macrophages, dendritic cells and B 
cells (58). Shortly after biosynthesis in the endoplasmic reticulum, CD1d is 
loaded with endogenous lipid by microsomal triglyceride transfer protein and 
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trafficked to the plasma membrane. CD1d then undergoes extensive recycling 
between the plasma membrane and lysosome, where saposins facilitate lipid 
exchange. 
 Saposins are a group of four lipid transfer proteins derived from a common 
precursor, termed prosaposin (59). A genetic link between iNKT cells and lipid 
metabolism was demonstrated in studies using prosaposin-deficient mice, which 
lack iNKT cells and display impaired ability to present iNKT ligand (60). The deep 
hydrophobic antigen- binding pocket of CD1d allows for glycolipid antigen binding 
(61) and, after trafficking to the plasma membrane, lipid antigen-loaded CD1d 
engages the invariant TCR on the iNKT cell leading to subsequent activation and 
rapid cytokine production. 
 In addition to this direct pathway of activation by glycolipid antigens 
presented on CD1d, iNKT cell activation can also occur via an indirect 
mechanism first involving APC activation (Figure 2). Briefly, TLR-mediated 
activation of APCs leads to proinflammatory cytokine production which, along 
with weak interaction of iNKT cells with endogenous antigens, can activate iNKT 
cells (62). 
 
iNKT Cells and Infection 
 Cells of the iNKT lineage are essential components in the fight against 
infectious agents. Much like the cells of the innate immune system, iNKT cells 
are capable of recognizing pathogenic structures of similar patterns. An 
infectious agent capable of eliciting an iNKT cell response is the Gram-negative 
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spirochete bacterium causative of Lyme disease: B. burgdorferi (63). In a study 
performed to elucidate the B. burgdorferi-mediated mechanism of iNKT cell 
activation, it was reported that BbGL-IIc, a galactosyl diacylglycerol comprising 
12% of the lipid content of B. burgdorferi, is responsible for proliferation and 
activation of splenic and hepatic iNKT cells derived from C57BL/6 mice. BbGL-IIc 
associated with CD1d and variants of this lipid were ineffective at eliciting similar 
activated phenotypes on iNKT cells (64). These data indicate that iNKT cells can 
respond to specific pathogen lipid components through direct engagement of 
their TCR. In a recent study, C57BL/6 mice lacking iNKT cells exhibited severe 
heart inflammation and bacterial burden in response to B. burgdorferi challenge. 
In contrast, it was found that C57BL/6 mice with functional iNKT cells were found 
to have reduced bacterial loads and mitigated symptoms of disease (65). In this 
infectious model, iNKT cells were found to migrate to infected sites of the heart 
and provide protection via secreted IFN- and macrophage activation. A different, 
well-studied example of iNKT cell activation via microbial glycolipids includes 
GSL-1 derived from Sphingomona paucimobilis (66). Just like BbGL-IIc, GSL-1 
was found to load on CD1d and produce an iNKT-cell-mediated response. The 
only characteristic shared by these two iNKT cell ligands is an -anomeric sugar 
attached to the different lipid groups (63). These examples of glycolipid 
recognition illustrate the ability of iNKT cells to behave like cells of the innate 
immune system by responding to similar molecular patterns associated with 
different pathogens. 
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iNKT Cells and Cancer 
 Harnessing cytotoxic effects of iNKT cells to targets responsible for the 
formation of cancer has been one of the main drivers of research for this cell 
type. The marine- sponge-derived synthetic iNKT cell ligand -GalCer was 
discovered by its ability to prevent metastatic tumor formation (50, 67). When 
iNKT cells were discovered to be the main cell type responsible for recognition of 
-GalCer, great excitement followed research to understand their mechanism of 
 
 
Figure 2. Potential mechanisms of iNKT cell activation. A, Direct activation of iNKT 
cells via exogenous gylcolipids, such as -GalCer, taken up by APCs and presented on 
CD1d. B, Indirect activation of iNKT cells via TLR activation of APCs. Proinflammatory 
cytokines, such as IL-12, produced during APC activation, activate iNKT cells in 
combination with weak interactions of the iNKT cells with endogenous antigens. 
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tumor suppression (68).This excitement has been met with difficulty to detect the 
endogenous lipid ligands present in cancer cells responsible for iNKT cell 
activation (69). Early studies of mice deficient in iNKT cells provided an indirect 
measure to study resistance to tumor formation. In murine models of tumor 
induction mediated by methylcholanthrene- induced fibrosarcomas, it was shown 
that passive transfer of iNKT cells provided protection against sarcoma formation 
(70). Initial findings of iNKT cell immunogenicity have driven scientific groups to 
produce iNKT cell vaccines that provide immunity against tumor formation. In an 
iNKT cell vaccine study (71), it was reported that loading of a non-immunogenic 
murine lymphoma cell line, A20, with -GalCer produced tumor-specific 
protective immunity. Mice re-challenged with A20 cells exhibited a memory 
phenotype protecting mice against lymphoma formation. These studies have 
shown the adaptive immune system becomes activated following innoculation 
with iNKT-cell-specific vaccine.  
 Adaptive immunity involvement is an interesting outcome and elucidating 
this mechanism would be a breakthrough in cancer research; it would provide a 
system that bridges innate and adaptive immunity and targets tumor cells. 
Translation of this protection to humans has proven difficult, as iNKT cell 
frequency is lower in human spleen, thymus and blood than in mice (53), and use 
of the anti-metastatic compound -GalCer can cause side effects affecting the 
cardiovascular system (see atherosclerosis section). Whether this protection 
translates to humans is a feat to be accomplished. 
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iNKT Cells and Autoimmunity 
 There is an intricate relationship between iNKT cell function and defects in 
the modulation of autoimmune disease. The majority of the information known 
about  iNKT cell modulation of disease comes from murine models of 
autoimmune disorders such as: experimental autoimmune encephalomyelitis 
(EAE), non-obese diabetic mice, graft transplantation rejection model 
representing human type I diabetes (T1D) and human graft-versus-host disease 
(72). A clue to the immunomodulatory ability of iNKT cells came from EAE 
studies where synthetic analogues of -GalCer were utilized to treat a peptide-
induced model of EAE (73). In this particular study, a peptide derived from myelin 
oligodendrocyte was used to induce CNS disease in C57BL/6 mice and iNKT-
cell-deficient (J281–/–) mice. C57BL/6 mice were protected from EAE by 
injection of -GalCer analogues while in iNKT-cell-deficient mice EAE 
progression was not altered. 
 Additionally, iNKT cells have been studied in the context of T1D. In studies 
of monozygotic twins suffering from T1D, lower numbers of iNKT cells and 
abnormal polarization of Th1 responses have been observed (74). This 
phenotype is similar to the non-obese diabetic mouse model (75), where iNKT 
cell number and function are also abnormal. Similar to the EAE model, 
restoration of functional V14+ T cells provides protection against T1D 
progression. These studies indicate that iNKT cells can be modulators of 
autoimmune pathogenesis by affecting responses mediated by cells of the 
adaptive immune system. These examples illustrate how iNKT cell function alters 
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progression of autoimmune disease. Although human studies of iNKT cell 
function in autoimmune diseases are limited in number and quality of controls, 
the presence of functional iNKT cells in humans makes this cell lineage a great 
target for therapy to modulate autoimmune disorders. 
  
iNKT Cells in Atherosclerosis 
 Given that lipid accumulation is a hallmark of atherosclerosis and the fact 
that iNKT cells are activated by glycolipid antigens, it is not surprising that iNKT 
cells were hypothesized to play a role in this inflammatory disease. In fact, iNKT 
cells have been found in human carotid artery plaques, specifically in the 
shoulder region of these lesions (76), as well as in human atherosclerotic tissue 
derived from abdominal aortic aneurysms (77). In addition, several different 
approaches have been taken to define the role of these unique cells in 
atherosclerosis using mouse models of the disease. 
 Given their strong association with decreasing inflammatory response, a 
reasonable hypothesis would be that iNKT cells are protective against 
progression of atherosclerosis. However, since 2004, several studies using both 
CD1d-deficient mice, which lack iNKT cells, have demonstrated that iNKT cells 
are pro-atherogenic. For example, when CD1d–/– mice were crossed onto the 
apoE–/– background, atherosclerosis was decreased (7–9) . In addition, wild-type 
CD1d–/– mice fed an atherogenic diet had decreased atherosclerotic lesions (8) 
compared to controls. It was also shown by our laboratory (7) and others (9) that 
repeated exogenous activation of iNKT cells by -GalCer (or the related 
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glycolipid OCH (8)) increases atherosclerosis in apoE–/– mice. Reciprocally, using 
an adoptive transfer model of atherosclerosis in which iNKT cells were 
transferred to RAG1–/–LDLr–/– mice, VanderLaan et al. (78) demonstrated that 
iNKT cells are pro-atherogenic in the absence of exogenous stimulation by -
GalCer. Studies in CD1d-deficient mice were further confirmed and refined when 
Rogers et al. (79) observed that loss of functionally active iNKT cells by using a 
targeted deletion of the J18 gene in LDLr–/– mice reduced the formation of early 
atherosclerotic lesions. These latter experiments demonstrated that the invariant 
type I NKT cells and not the type II NKT cells (which have variant but limited TCR 
usage) were responsible for increasing lesion formation in the mouse models of 
atherosclerosis. 
 Interestingly, as with many effects of immunity on atherosclerosis, the 
effects of iNKT cells appear to be most influential during early lesion progression. 
This was reported by Aslanian et al. (80) who demonstrated that absence of 
iNKT cells in LDLr–/– mice leads to decreased early atherosclerosis but did not 
influence later, more advanced lesions, and that the iNKT cell contribution to 
lesion progression is transient. More recently, an adoptive transfer study using 
various subsets of iNKT cells transferred to apoE–/– mice fed high-fat diet showed 
that CD4+ iNKT cells are the subset responsible for pro-atherogenic activity of 
iNKT cells (81). This appeared to be related to the decreased expression of the 
inhibitory surface receptor Ly49 on CD4+ iNKT cells and the increased ability of 
CD4+ iNKT cells to secrete proinflammatory cytokines such as IL-2, TNF- and 
IFN- upon stimulation with -GalCer. These studies illustrate the complexity of 
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the iNKT cell population and highlight the importance of considering their intricate 
functions in the design of lipid-mediated therapeutics for human inflammatory 
diseases. 
 Although most studies assign a pro-atherogenic role for iNKT cells, one 
study suggests the opposite effect of iNKT cells and therefore deserves 
discussion. van Puijvelde et al. (82) observed an atheroprotective role for iNKT 
cells in one model of atherosclerosis. Specifically, exogenous activation of iNKT 
cells by -GalCer injections protected LDLr–/– mice, but not apoE–/– mice, from 
carotid atherosclerosis. However, in contrast to the previous studies which 
examined aortic sinus atherosclerotic lesions in response to -GalCer, this study 
used a model of carotid atherosclerosis induced by placement of perivascular 
collars around the carotid arteries. These findings suggest that discrepancies in 
the roles of iNKT cells in atherosclerosis may be a result of the models used or 
that iNKT cells play different roles in different anatomic sites of the vasculature. 
At any rate, these diametrically opposed results indicate that further 
investigations are needed to fully determine the capabilities of iNKT cells to 
promote or protect against atherosclerosis in different settings. 
 
Effects of Circulating Lipids on iNKT Cell Function 
 It is well established that increased lipid accumulation is associated with 
atherosclerosis in both humans and genetically altered mice. Interestingly, van 
den Elzen et al. (83) have shown that circulating lipoproteins, such as very low 
density lipoproteins and, more specifically, those associated with apoE, can 
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enhance iNKT cell responses to glycolipid antigen presented by human dendritic 
cells. The authors suggest that perhaps lipoprotein mediated uptake of bacterial 
lipid antigens, such as those associated with Mycobacterium spp., and the 
subsequent activation of NKT cells is an important means to enhance immunity. 
In addition, it has recently been shown that B cells, which can present lipid 
antigen to iNKT cells, use an apoE-dependent pathway of lipid antigen 
presentation, and that these APCs are more dependent upon this pathway than 
dendritic cells (84). Studies from our laboratory (7) have shown that iNKT cell 
numbers in the spleen and liver, as well as iNKT-cell-induced IFN- production, 
are decreased in apoE–/– mice in an age-dependent manner, which correlates 
with increased levels of circulating lipids in these mice. Consistent with these 
results, B6 mice fed a high-fat diet have suppressed iNKTcell-derived IFN- 
production in response to -GalCer (85). To further demonstrate the importance 
of lipids in iNKT cell responses, LDLr–/– mice fed Western-type diet accumulate a 
CD1d-dependent antigen in the serum, and the increased level of this antigen is 
consistent with the presence of LDL (78). Collectively, these studies support the 
relationship between iNKT cells and lipoproteins and substantiate the possible 
link between infection, immunity and the progression of atherosclerosis. 
 Given that uptake and lysosomal processing of glycolipid is essential to 
iNKT cell activation, determining the key players in this pathway is essential. The 
study by van den Elzen et al. mentioned above, showed that apoE and one of its 
receptors, the LDLr, are involved in the uptake of glycolipid antigen and 
subsequent activation of iNKT cells. Another member of the LDLr gene family, 
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the low density lipoprotein receptor-related protein (LRP) has vital structural 
resemblance to the LDLr and recognizes a wide array of diverse ligands, 
including apoE-enriched lipoproteins. LRP is a ubiquitously expressed, multi-
ligand receptor with many functions which include lipoprotein transport, cell 
surface protease activity, and cellular uptake and lysosomal delivery of secreted 
prosaposins, saposin precursors (86). Importantly, saposins are required for the 
loading and unloading of CD1d within the lysosomes (see iNKT cell ontogeny 
section). In addition to its role in lipoprotein metabolism, LRP has been shown to 
enhance antigen uptake by monocytes and macrophages (87) and is involved in 
control of cellular entry of bacterial toxins and viruses (88). Molecules bound to 
LRP are internalized and delivered to the lysosomes for subsequent degradation. 
Given that LRP is involved in the capture of saposin precursors, important for the 
CD1d pathway, and that LRP has been shown to play a role in the immune 
response, further studies are warranted to identify a role for this receptor in iNKT 
cell activation. 
 
Summary 
 In summary, iNKT cells are a specialized subset of T cells which 
recognize glycolipid antigens. These unique cells have been studied for their 
involvement in several inflammatory and autoimmune diseases. Because of their 
ability to quickly secrete large amounts of pro- and anti-inflammatory cytokines, 
these cells present an attractive target for potential therapies in human disease. 
Given that manipulation of iNKT cells has been proposed in human disease 
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therapy, further investigation into how iNKT cells are influenced by their 
environment and how this might lead to unwanted side effects, such as an 
increased risk of CVD, could have obvious effects on potential therapeutic 
strategies. Here, we have highlighted the importance of these unique cells of the 
immune system within several human pathologies, including those associated 
with increased circulating lipids. In the following chapters, we provide evidence 
for the influence of a dyslipidemic environment on iNKT cell function, and that 
molecules involved in lipid metabolism may also play a role in iNKT cell 
activation. 
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CHAPTER II 
 
SPONTANEOUS INKT CELL ANERGY IN A MOUSE MODEL OF 
DYSLIPIDEMIA 
 
Introduction 
 
Although few “natural” ligands of iNKT cells have been identified, it is well 
established that iNKT cells respond strongly to, and are specifically activated by 
-galactosylceramide (-GalCer) (50). Animal studies have demonstrated that 
activation of iNKT cells by in vivo administration of -GalCer can mediate both 
protective and pathological immune responses.  For example, -GalCer has 
been shown to suppress inflammation in mouse models of autoimmune diseases 
such as type 1 diabetes and  multiple sclerosis (45, 46).  Our laboratory (7), as 
well as others (8, 9, 78), have shown that activation of  iNKT cells with -GalCer 
is pro-atherogenic.   Because of the strong immunoregulatory potential of iNKT 
cells,  -GalCer has been proposed as a viable human therapy for autoimmune 
and inflammatory diseases, as well as cancer (89). Therefore, understanding 
how environmental factors can influence or skew the iNKT cell response to 
glycolipids is extremely important. 
Nakai et al, demonstrated that C57BL/6 mice fed a high fat diet (8) have 
decreased iNKT cells numbers and functions, as measured by cytokine 
secretion. Our laboratory has reported similar changes in iNKT cell dynamics in 
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spontaneously dyslipidemic apolipoprotein E-deficient (apoE-/-) mice (7).  These 
studies demonstrate, perhaps not surprisingly, that iNKT cells are extremely 
sensitive to their lipid environment. It is not known, however, whether diet and 
lipid-mediated changes in iNKT cell functions are due to intrinstic changes in 
iNKT cells or defects in the ability of antigen presenting cells, such as dendritic 
cells, to activate iNKT cells.  
In the current study we investigated the mechanism(s) by which 
spontaneous dyslipidemia decreases the responsiveness of iNKT cells to 
exogenous glycolipid antigen.  We demonstrate that hyperlipidemia chronically 
activates iNKT cells, placing them in an irreversible anergic-like state, and that 
these changes in the iNKT cell phenotype are irreversible once established, and 
independent of the source of antigen presenting cell. 
  
 
Methods 
 
Animals.  Male C57BL/6J (B6), B6.129P2-Apoetm1Unc/J (apoE-/-), and LDLr-/- mice 
were originally purchased from Jackson Laboratories (Bar Harbor) and 
maintained in our colonies under pathogen-free conditions. ApoE-/- mice have 
been backcrossed to B6 mice for greater than 10 generations.  Animals were fed 
standard chow diet ad libitum. All animal studies were approved by the 
Institutional Animal Care and Use Committee of Vanderbilt University (Nashville, 
TN). 
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Reagents.  α-GalCer (KRN7000) was obtained from Kirin Brewing Company 
(Japan) and reconstituted in PBS containing 0.5% polysorbate-20 (Sigma 
Aldrich). GGC (PBS-18) was described previously (90). Fluorescently labeled 
tetrameric CD1d molecules loaded with α-GalCer (CD1d tetramers) were 
obtained from the National Institute of Allergy and Infectious Diseases (NIH 
tetramer facility). For blocking experiments, anti-mouse PD-1 (91) and rat anti-
mouse PD-L2 (TY25) (92) monoclonal antibodies were described previously. 
Anti-TCRβ-FITC, anti-PD-1-PE, anti-PD-L1-PE, anti-PD-L2-PE, anti-B220-
PerCP, and anti-Ly49-PE were obtained from BD Pharmingen. Anti-CD11c-
PerCP-Cy5.5 was obtained from eBioscience. For recognition of CD1d:-GalCer 
complexes, L363 monoclonal antibody was used as previously described (93).  
For the in vitro iNKT cell hybridoma assay, the DN32.D3 and N38-2C12 
hybridomas were kindly provided by Dr. Albert Bendelac (University of Chicago, 
IL). The noncanonical iNKT cell hybridoma N37-1A12 has been previously 
described (94). CFSE labeling kit was purchased from Invitrogen. 
 
Flow Cytometry.  Single-cell suspensions of the spleen and liver were prepared, 
and stained with fluorescently-labeled monoclonal antibodies as described 
previously (95). Flow cytometry was performed using a FACS Calibur instrument 
(BD Pharmingen) and the data were analyzed using FCS Express software (De 
Novo Software). The iNKT cell population was defined as B220- TCRβint 
tetramer+.  
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Intracellular cytokine staining.  For intracellular cytokine staining, splenocytes  
were stimulated with 25-100 ng/ml -GalCer in the presence of GolgiStop for 4 
hours. Cells were fixed and permeabilized with Cytofix/Cytoperm (BD 
Pharmingen) reagents according to the manufacturer‟s protocol.  
 
ELISA.  Mouse IL-4 and IFN- were measured by standard sandwich ELISA 
according to the manufacturer‟s protocol (BD Pharmingen). 
 
Measurement of in vitro and in vivo responses to -GalCer.  4 g -GalCer 
reconstituted in 0.5% polysorbate (vehicle) was i.p. injected into mice, 
splenocytes stained and analyzed by flow cytometry, and serum IL-4 and IFN- 
measured by ELISA. In vitro, splenocytes were plated in 96-well plates at 2.5x105 
cells per well in RPMI-1640 (Hyclone) containing 10% fetal bovine serum 
(Sigma), penicillin-streptomycin with 50 µmol/L L-glutamine (Gibco), and 50 
µmol/L β-mercaptoethanol (Sigma) in the presence of varying concentrations of 
-GalCer. Supernatants were collected after 72 hours of culture and cytokine 
levels were determined by ELISA. For proliferation studies, splenocytes were 
labeled with CFSE and cultured in the presence of 50 U/ml recombinant mouse 
IL-2 (BD Biosciences) as described previously (96). 
 
Isolation of splenic DCs. Splenic DCs were isolated as described previously (95). 
Briefly, spleens were digested with 1 mg/ml collagenase type II (Sigma) in Hank‟s 
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Balanced Salt Solution (Mediatech) for 30 minutes. DCs were enriched by 
magnetic sorting using anti-CD11c microbeads (Miltenyi Biotech) according to 
the manufacturer‟s protocol. The purity of the enriched CD11c+ population was 
80-85% (data not shown). Purified DC were pulsed with 50 ng/ml -GalCer for 30 
min, washed twice with RPMI medium, and then cultured (5x104 cell/well of a 96-
well plate) with iNKT cells. Bone marrow derived DCs were isolated and cultured 
as previously described (97). 
 
Enrichment of iNKT cells. Liver iNKT cells were enriched as previously described 
(95). Briefly, livers were perfused with PBS, digested with type II collagenase 
(Sigma), and then pressed through a 70 µm cell strainer. To remove adherent 
APCs, two rounds of panning, 1 hour each, were performed. The enriched iNKT 
cells were co-cultured for 48 hours with -GalCer-loaded DCs as described 
above.  
 
ConA-induced hepatitis. Mice were injected i.v. with 350 μg ConA (Sigma) in 200 
μl PBS, and sacrificed 24 hours post-injection. Hematoxylin and eosin staining of 
paraffin-embedded livers sections was performed as previously described (98). 
 
Serum lipid and free fatty acid analyses. Total serum cholesterol and triglyceride 
were measured in fasting mice as previously described (99). Free fatty analysis 
was conducted by gas chromatography by the Vanderbilt Mouse Metabolic 
Phenotyping Center. 
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Statistics. Statistical significance between two groups was determined using a 
Student‟s t test, and significance between multiple groups was determined using 
one-way ANOVA with Newman-Keuls multiple comparison test for post hoc 
analysis. A value of p<0.05 was considered statistically significant and all 
statistical analyses were performed using GraphPad Prism software. 
 
Results 
 
ApoE-/- mice have decreased percentages and absolute numbers of 
peripheral iNKT cells.    
 Previously, our lab demonstrated that apoE-/- mice have an age-
associated decrease in iNKT cell numbers (7); however it was not determined 
whether this apparent decrease was due to systemic changes in iNKT cells or 
was the result of impaired iNKT cell development in the thymus.  To address this 
question, we compared iNKT cell numbers in the spleen, liver, and thymus of 
older (≥ 16 week-old) age matched B6 and apoE-/- mice.  As previously reported 
(7), we observed a significant decrease in the percentages of iNKT cells 
(TCRinttetramer+) in livers and spleens of apoE-/- mice compared to B6 mice 
(Figure 3A).  Given that there was no difference in the numbers of total 
lymphocytes in liver and spleen, the decrease in iNKT cell percentages translates 
into a decrease in absolute numbers of iNKT cells (Figure 3B). Thymic iNKT cell 
percentages and absolute numbers did not differ between apoE-/- and B6 mice 
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(Figure 3A and B).  In addition, surface markers of thymic iNKT cell 
differentiation, CD44 and NK1.1, were not different between the two strains 
(Figure 3C).  The data suggest that defects in iNKT cell numbers occur in the 
periphery and are not due to decreased thymic differentiation. 
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Figure 3. Decreased iNKT cell numbers and functions in apoE
-/-
 mice. A, iNKT cell 
percentages in the thymus, spleen, and liver of B6 and apoE
-/-
 mice. Shown are representative 
dot plots of 3 experiments with 3 mice per group. B, Absolute iNKT cell numbers in the spleen 
and thymus. Bars represent the mean and standard error. Data are representative of 3 
experiments. C, Flow cytometry analyses of NK1.1 and CD44 on iNKT cells from the thymus 
of B6 and apoE
-/-
 mice. D, Splenocytes from B6 and apoE
-/-
 mice were cultured for 72 hours in 
the presence of the indicated concentrations of -GalCer. IFN- and IL-4 were determined by 
ELISA. Data points represent the mean and standard error of 3 mice in each group.  Shown is 
one representative experiment of 3.  E, Mice were injected i.p. with 4 µg -GalCer and 
cytokine production was determined by ELISA. Serum IFN- was measured 24h post-injection 
and IL-4 was measured 2h post-injection. Shown are the mean and SD of 3 mice per group. F, 
Mice were injected with 4 µg -GalCer, and 24h post-injection, activation of splenic B cells, 
NK cells, T cells and dendritic cells was determined by flow cytometry.  Shown are 
representative histograms of 5 mice in each group. *p<0.05 as determined by Student‟s t test. 
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Because of this, we hypothesized that spontaneous hyperlipidemia and/or 
spontaneous accumulation of circulating inflammatory free fatty acids (FFA), as 
seen in apoE-deficiency, could affect iNKT cell responsiveness. Not surprisingly, 
when we stimulated whole splenocytes with -GalCer in vitro, we observed 
blunted IL-4 and IFN- production by apoE-/- splenocytes compared to age-
matched controls (Figure 3D).  Notably, the decrease in cytokine production in 
apoE-/- cultures was greater than what would be expected if it was due only to 
decreased absolute iNKT cell numbers.  To determine if this degree of iNKT cell 
hyporesponsiveness also occurred in vivo, we injected apoE-/- and B6 mice with 
4 g/mouse of -GalCer or vehicle intraperitoneally.  At 2 and 24 hours following 
injection (times associated with peak iNKT cell-mediated IL-4 and IFN- 
production, respectively), we observed that, similar to in vitro analyses, the in 
vivo response to -GalCer was also blunted in apoE-/- mice, as indicated by 
serum IFN-and IL-4 (Figure 3E).  This was associated with a decreased ability 
to transactivate other immune cells downstream of iNKT cell activation, such as 
B cells, NK cells, T cells, and DCs (Figure 3F).  
These data show that iNKT cells from apoE-/- mice are hyporesponsive to 
exogenous stimulation; however it is unclear whether this decreased function is 
due to genetic deficiency of the APOE gene. Although secretion of apoE protein 
by iNKT cells has not been previously reported, we did not anticipate this to be 
the case given that the primary function of iNKT cells is to rapidly secrete large 
amounts of cytokines to aid in regulation of immune responses. However, if iNKT 
cells produce apoE, this finding could affect our interpretations of the results 
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using an apoE-deficient mouse model. To determine whether iNKT cells 
synthesize and secrete apoE in vivo, we isolated wild-type primary iNKT cells 
from the spleen. Peritoneal macrophages from B6 and apoE-/- mice were used as 
positive and negative controls, respectively. As expected, primary iNKT cells, in 
addition to iNKT cell hybridomas, do not express apoE protein, as determined by 
Western blot analyses (Figure 4). 
 
 
 
 
 
Decreased cytokine production in apoE-/- mice following -GalCer 
stimulation is iNKT cell specific.   
 Although the apoE-/- mice had a 2-fold decrease in the absolute numbers 
of iNKT cells in the spleen and liver, the cytokine response to -GalCer 
stimulation in vitro and in vivo was disproportionately suppressed and could not 
 
 
 
Figure 4. iNKT cells do not express apoE. ApoE expression, as determined by 
Western blot, in 3 iNKT cell hybridoma cell lines (DN32D3, N371A12, and 
N382C12) and primary iNKT cells isolated from B6 spleens. Peritoneal 
macrophages elicited from B6 and apoE
-/-
 mice were used as positive and 
negative controls, respectively.  
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be completely attributed to decreased iNKT cell numbers.  Because in vivo 
activation or in vitro stimulation of splenocytes with -GalCer allows for the 
potential of multiple cellular cytokine sources, we conducted intracellular cytokine 
staining on iNKT cells isolated from apoE-/- and B6 mice.  Following a 4 hour in 
vitro stimulation with -GalCer, we observed a significant decrease in IFN- 
positive splenic iNKT cells in apoE-/- mice compared to controls (Figure 5A). The 
percentage of IL-4 positive iNKT cells was reduced in apoE-/- mice compared to 
B6 mice but did not reach statistical significance (Figure 5B).   
 
 
 
 
 
 
 
Figure 5. Decreased cytokine production is iNKT cell specific. Splenocytes from B6 
and apoE
-/-
 mice were stimulated for 4 h in vitro with 25 ng/ml of -GalCer and intracellular 
IFN- and IL-4 were determined by flow cytometry. A, Representative dot plots from 3 
experiments. B, Percentages of IFN- 
+
 (left panel) and IL-4
+
 (right panel) iNKT cells. 
*p<0.05 as determined by Student‟s t test. 
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iNKT from apoE-/- mice cells resemble exhausted, chronically activated 
cells.   
 Because we observed a decrease in the ability of apoE-/- splenic iNKT 
cells to produce cytokines upon stimulation with -GalCer, we examined the 
ability of iNKT cells to expand in vivo following specific activation.  Previous 
studies have demonstrated that upon in vivo activation with -GalCer, iNKT cells 
respond by initially contracting at 24 hours and then expanding 3 days following 
-GalCer injection (96).  iNKT cells that have been rendered anergic due to a 
previous antigen exposure, however, fail to respond in this manner (96).  
Therefore, to test the hypothesis that iNKT cells in hyperlipidemic apoE-/- mice 
display an anergic phenotype, we injected B6 or apoE-/- mice with 4 g/mouse of 
-GalCer (or vehicle) intraperitoneally, and tracked changes in the splenic iNKT 
cell population over time.  As shown in Figure 6A, the B6 iNKT cells responded 
as expected following -GalCer injection.  Although iNKT cells from apoE-/- mice 
initially contracted 24 hours following injection, these cells showed blunted 
expansion at three days. Quantitatively, this resulted in a significant decrease in 
the ability of iNKT cells from apoE-/- mice to proliferate in response to -GalCer 
stimulation (Figure 6B).  This difference was also significant following 
normalization to the baseline absolute numbers of iNKT cells (Figure 6C).  To 
determine whether these changes in iNKT cell responses had physiologic 
consequences, we compared apoE-/- and B6 mice in iNKT cell-dependent ConA-
induced hepatitis.  As expected, livers from apoE-/- mice showed decreased 
inflammatory infiltration compared to B6 mice (Figure 6D). Therefore, iNKT cells 
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from apoE-/- mice respond to antigen stimulation in vivo similar to those from wild-
type mice rendered anergic by repeated activation, and this abrogation of iNKT 
cell function is relevant to modulation of disease pathology. 
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Figure 6. iNKT cells from apoE-/- mice display an anergic phenotype. A, B6 and apoE-/- 
mice were injected with 4 µg -GalCer and splenic iNKT cells were analyzed by flow 
cytometry at 0, 24 hours, 3 days, 7 days, and 1 month following injection. Shown are 
representative dot plots of 3 mice per group gating on B220
-
 cells. B, Flow cytometry data as 
shown by percent tetramer
+
 cells (gated on B220
-
TCR
int
). C, Fold change over baseline in 
percent tetramer
+
 cells. D, B6 and apoE
-/-
 mice were injected i.v. with 350 µg ConA in 200 µl 
PBS and sacrificed 24 hours later. ConA-induced hepatitis (black arrowheads show areas of 
lymphocyte infiltration) was assessed by hematoxylin and eosin staining of paraffin-embedded 
liver sections. Shown are representative sections from 4 mice per group. 
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Changes in iNKT cell activation are cell autonomous and not due to 
defective antigen presentation.   
 Given that CD1d on antigen presenting cells is required for presentation of 
glycolipid antigen to iNKT cells, and previous reports suggested that apoE 
increases uptake and presentation of glycolipid antigens by DCs (83), we 
isolated splenic DCs from B6 and apoE-/- mice and compared CD1d expression. 
Flow cytometry analyses demonstrated that CD1d expression was not decreased 
on apoE-/- DCs compared to B6 DCs (Figure 7A). To examine differences in 
glycolipid antigen presentation, splenocytes from B6 and apoE-/- mice were 
loaded with the -GalCer precursor galactosyl(α1-2)galactosylceramide (GGC) in 
vitro, and then incubated with a monoclonal antibody specific to CD1d:α-GalCer 
complexes (L363) (93). GGC must undergo lysosomal processing to be loaded 
on CD1d molecules for surface presentation.  Flow cytometry analyses showed 
that apoE-/- DCs exhibited increased CD1d loading and presentation of 
processed GGC at the cell surface. (Figure 7B).  
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 In addition, to demonstrate that the in vivo changes we observed in iNKT 
cells from apoE-/- mice were not due to defective ability of apoE-/- DCs to process 
and present antigen, we grew bone marrow-derived DCs from B6 and apoE-/- 
mice. DCs were pulsed in vitro with -GalCer, and then incubated with the V14+ 
iNKT cell hybridoma DN32.D3.  We observed that DCs from both strains of mice 
 
Figure 7. Dendritic cells from apoE
-/-
 mice retain the ability to activate iNKT cells.  
A, CD11c
+
 splenic dendritic cell expression of CD1d as determined by flow cytometry. B, 
Splenocytes from B6 and apoE
-/-
 mice were incubated 18 hours with 50 ng/ml GGC, then 
stained with 1 µg/ml L363 mAb to detect surface CD1d:-GalCer complexes. Flow 
cytometry analyses were performed by gating on CD11c
+
 cells. Shown are representative 
histograms of 2 experiments using 3 mice per group. C, CD11c
+
 dendritic cells were purified 
from spleens of B6 and apoE
-/-
 mice, loaded with 50 ng/ml -GalCer for 30 min, then 
incubated with the iNKT cell hybridoma DN32.D3 for 48 hours. Activation of the hybridoma, 
as measured by IL-2 production in culture supernatants, was determined by ELISA. -
GalCer alone (with no DC) did not result in IL-2 production. D, Purified splenic DCs were 
incubated with 50 ng/ml -GalCer for 30 min, then added to purified iNKT cells and co-
cultured for 72 hours. IFN (left panel) and IL-4 (right panel) were determined by ELISA. 
*p<0.05 when compared to B6 DCs cultured with B6 iNKT cells, and 
†
p<0.05 when 
compared to apoE
-/-
 DCs cultured with B6 iNKT cells, as determined by 1way ANOVA. 
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were able to activate the iNKT cell hybridoma with equal efficiency (Figure 7C). 
Finally, when lethally irradiated LDLr-/- mice were reconstituted with B6 bone 
marrow (to restore the apoE-LDLr axis on hematopoietic cells, yet retain 
dyslipidemia), similar decreases in iNKT cell functions were observed when mice 
were fed chow diet (Figure 8).   
 
 
 
 
 
Figure 8. LDLr
-/-
 mice transplanted with B6 bone marrow are dyslipidemic and 
have decreased iNKT cell activation. B6 and LDLr
-/-
 mice were lethally irradiated and 
transplanted with B6 bone marrow at six weeks of age. Mice were fed standard chow 
diet and sacrificed at 6 weeks post-transplant. A, Serum cholesterol (left panel) and 
triglyceride (right panel) was determined by standard colorimetric assay at time of 
sacrifice. B, Serum lipoprotein profile was determined by fast-performance liquid 
chromatography. C, Splenocytes were cultured for 72 hours in the presence of 50 
ng/ml of -GalCer, and in vitro IFN (left panel) and IL-4 (right panel) were determined 
by ELISA. *p<0.05 as determined by Student‟s t test. 
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 To determine whether iNKT cells from apoE-/- mice can respond to wild 
type APCs, splenic DCs were isolated from B6 and apoE-/- mice, pulsed with -
GalCer, and mixed with iNKT cells from B6 or apoE-/- mice.  Analysis of cultured 
supernatants demonstrated that, although the apoE-/- DCs were able to stimulate 
cytokine production by B6 iNKT cells, the apoE-/- iNKT cells had a reduced ability 
to respond to B6 DCs (Figure 7D).  Collectively, these data demonstrate that, in 
our system, absence of apoE does not directly affect antigen presentation or 
iNKT cell responsiveness but that changes are more likely due to a dyslipidemic 
environment. 
 
iNKT cells from apoE-/- mice appear to be spontaneously activated.   
 It has been previously demonstrated that upon activation, the surface TCR 
expression on iNKT cells is downregulated via internalization (100).  To 
determine whether this phenomenon was responsible for the apparent decrease 
in absolute numbers of iNKT cells in apoE-/- mice, we performed intracellular and 
extracellular staining on splenocytes using CD1d/-GalCer tetramers and anti-
TCRantibodies.  We observed that spleens of B6 mice had similar percentages 
of iNKT cells following both intracellular and extracellular staining (Figure 9A, 
comparing surface to surface+internalized).  Because surface receptors may be 
stained during the intracellular staining process, these data suggest that the 
majority of the control iNKT cells have not internalized their TCR and are not 
activated.  In contrast, intracellular staining of apoE-/- splenocytes demonstrated 
an increase in the percentage of iNKT cells that had internalized their TCR 
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supporting the hypothesis that iNKT cells from hyperlipidemic animals are 
spontaneously activated.  Interestingly, when the numbers of iNKT cells that had 
internalized their TCR were accounted for, the apoE-/- mice had increased 
numbers of iNKT cells compared to B6 control mice. These data suggest that 
iNKT cells from hyperlipidemic apoE-/- mice (>12 weeks of age) are 
spontaneously activated and have internalized their TCR, accounting for the 
decreased detection by conventional surface staining. In contrast, ex vivo 
analyses of iNKT cells from young B6 and apoE-/- mice (5 weeks of age) revealed 
no differences in intracellular and extracellular TCR between the two groups 
(Figure 9B), suggesting that iNKT cells from apoE-/- mice are not spontaneously 
activated at an early age.  
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Figure 9. Increased TCR internalization in iNKT cells from aged apoE
-/-
 mice. iNKT 
cells from A,16-20 week old and B, 5 week old B6 and apoE
-/-
 mice and were stained for 
internalized and surface TCR expression and analyzed by flow cytometry. Internalized 
TCRwas determined by subtracting surface TCR from surface+internalized TCR. Shown 
are representative histograms from 3 mice per group.*p<0.05 as determined by Student‟s t 
test 
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Recent studies have demonstrated that T cells from mice with chronic viral 
infection express increased levels of the inhibitory markers Programmed Death-1 
receptor (PD-1) and PD-1 ligand-1 (PD-L1) (101).  Increased expression of PD-1 
and PD-L1 has also been demonstrated on iNKT cells rendered anergic by -
GalCer stimulation (102, 103).  Given that iNKT cells from hyperlipidemic apoE-/- 
mice appear to be spontaneously anergic both ex vivo and in vivo, we examined 
the expression of the inhibitory markers PD-1, PD-L1, PD-1 ligand-2 (PD-L2), 
and Ly49 on iNKT cells of naïve B6 and apoE-/- mice.  Flow cytometry analyses 
demonstrated that, consistent with previous reports, iNKT cells from B6 mice 
have some constitutive expression of PD-1, PD-L1 and PD-L2 (Figure 10A, right 
panels); however, the percentage of PD-1 positive iNKT cells was significantly 
increased in apoE-/- mice (Figure 10B).  These increases were not observed in 
iNKT cells from young 5- to 6-week-old apoE-/- mice (Figure 10A, left panels), 
demonstrating that changes in iNKT cells were acquired and not directly the 
result of developmental effects of apoE-/- deficiency. These data indicate that 
apoE-/- iNKT cells exhibit an exhausted phenotype perhaps due to increased 
activation by accumulation of endogenous lipid antigens.  
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PD-1 blockade can neither rescue nor prevent downregulation of iNKT cell 
responses in apoE-/- mice.   
 To determine whether blockade of PD-1 could restore apoE-/- iNKT cell 
responses as previously described (102), we incubated whole splenocytes from 
naïve B6 and apoE-/- mice with 50 ng/ml -GalCer in the presence of a PD-1 
blocking antibody or isotype control antibody.  Analysis of 72 hour supernatants 
demonstrated a partial increase in cytokine secretion in apoE-/- mice (Figure 
11A); however, PD-1 blockade did not result in normalization of cytokine levels in 
supernatants of apoE-/- mice.  These data suggest that blocking PD-1 cannot 
rescue the anergic phenotype of apoE-/- iNKT cells. 
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Figure 10. Increased PD-1 expression by iNKT cells from aged apoE
-/-
 mice. A, Ex vivo 
PD-1, PD-L1, and PD-L2 expression on iNKT cells from 5-6 week old (left panels) and 16-20 
week old (right panels) B6 and apoE
-/-
 mice. Shown are representative histograms from 3 
experiments. B, Percent PD-1
+
 iNKT cells ex vivo in 16-20 week old B6 and apoE
-/-
 mice. 
*p<0.05 as determined by Student‟s t test. 
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Previous work by Parekh et al, (96) demonstrated that, although PD-1 
blockade could not rescue anergic iNKT cells, it could prevent the development 
of anergy in this cell population if conducted before activation with -GalCer.  To 
determine whether this also applied to our apoE-/- model, we injected apoE-/- 
mice with anti-PD-1 or control rat immunoglobulin beginning at weaning 
(approximately 4 weeks of age).  Mice received antibody for 6 weeks after which 
responses to -GalCer were analyzed.  We observed that PD-1 blockade could 
not prevent induction of iNKT cell anergy in apoE-/- mice (Figure 11B).  These 
data suggest that upregulation of PD-1 is not the primary mechanism by which 
iNKT cells become non-responsive in apoE-/- mice. 
 
41 
 
 
 
 
Exogenous IL-2 restores apoE-/- iNKT cell proliferation in vitro.   
 It is known that administration of exogenous cytokines, such as IL-2, can 
overcome conventional T cell exhaustion, as well as iNKT cell anergy (96). Given 
that iNKT cells from apoE-/- mice display an anergic-like phenotype, we tested the 
ability of exogenous IL-2 to restore iNKT cell responses in vitro.  Splenocytes 
from B6 and apoE-/- mice were labeled with CFSE and stimulated with -GalCer 
in the presence or absence of IL-2. As shown by the CFSE dilution profile of 
tetramer+ cells (Figure 12), iNKT cells from apoE-/- mice displayed decreased 
 
 
Figure 11. PD-1 blockade is not sufficient to restore or prevent iNKT cell 
responsiveness. A, Splenocytes were cultured in vitro in the presence or absence of -
GalCer, with 50 µg/ml of control Ig, anti-PD-1, or anti-PD-L2 antibodies. After 72 hours, 
IFN- (top panel) and IL-4 (bottom panel) were determined by ELISA in culture 
supernatants. B, B6 and apoE
-/-
 mice were injected with control Ig or anti-PD-1 antibodies 
for 6 weeks, beginning at weaning. Mice were sacrificed and splenocytes were cultured 
with 50 ng/ml -GalCer for 72 hours and IFN- (top panel) and IL-4 (bottom panel) were 
determined by ELISA. *p<0.05 as determined by Student‟s t test.  
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proliferation in response to -GalCer as compared to B6 iNKT cells. Consistent 
with previous studies (96), addition of IL-2 resulted in restoration of the ability of 
apoE-/- iNKT cells to proliferate. These data indicate that iNKT cells from 
hyperlipidemic apoE-/- mice are anergic, and that IL-2 is sufficient to overcome 
this anergy in vitro. 
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Figure 12. IL-2 overcomes iNKT cell anergy in vitro. Splenocytes from B6 and apoE
-/-
 mice 
were labeled with CFSE and cultured for 24 hours with -GalCer (100 ng/ml) with or without 
IL-2 (50 U/ml). The cells were then washed, and cultures were continued for an additional 72 
hours without -GalCer, in the presence or absence of IL-2. After culture, CFSE dilution was 
analyzed on iNKT cells. Shown are representative histograms from 3 mice per group. *p<0.05 
as determined by Student‟s t test. 
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Discussion 
 
 iNKT cells are a unique subset of T cells that recognize glycolipid antigens 
and play a role in the regulation of inflammation and immunity.  Furthermore, our 
laboratory (7) and others (8, 9, 78), have shown that activation of iNKT cells is 
proatherogenic. During conditions of spontaneous hyperlipidemia in apoE-/- mice 
(7) and diet-induced dyslipidema (8), iNKT cell numbers and functions are 
decreased.  However, the etiology behind these changes is not yet known. 
Modulation of iNKT cell responses is being clinically tested as a possible 
therapeutic for cancer (104), diabetes (105), and HIV (106) in humans. In 
addition, it has been hypothesized that activating iNKT cells during immunization 
is a superior vaccination strategy (107). Thus, it is imperative to understand how 
the lipid environment might dampen or skew the iNKT cell response.   
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Figure 13. Liver iNKT cells from apoE-/- mice produce higher levels of IFN 
compared to B6 controls. Liver lymphocytes from B6 and apoE-/- mice (20 weeks of 
age) were stimulated for 4 h in vitro with 100 ng/ml of -GalCer and intracellular IFN- 
and IL-4 were determined by flow cytometry. Percentages of IFN 
+
 (left panel) and IL-4
+
 
(right panel) iNKT cells. *p<0.05 as determined by Student‟s t test. 
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 In the current study, we sought to examine the mechanisms by which 
chronic hyperlipidemia might decrease iNKT cell numbers and functions.  We 
observed that apoE-/- mice have decreased numbers of iNKT cells in spleens and 
livers compared to B6 controls, and that iNKT cells present in the spleens of 
apoE-/- mice have an impaired ability to respond to exogenous stimulation by the 
glycolipid -GalCer. This decreased cytokine production seemed to affect IFN- 
responses more than IL-4 suggesting that Th1 responses may be more effected 
than Th2.   Interestingly, liver iNKT cells from apoE-/- mice produced higher levels 
of IFN- compared to B6 controls (Figure 13). However, both apoE-/- and B6 mice 
had a very low percentage of liver iNKT cells that was cytokine positive following 
stimulation.  Therefore, it is difficult to determine the impact of these data, 
although, it is possible that liver iNKT cells are already somewhat non-responsive 
to ex vivo stimulation due to the high frequency of lipid in the liver. 
 It is well established that glycolipids play an important role in the 
development of iNKT cells within the thymus, and that normal thymic 
development of these iNKT cells requires the recognition of natural lipid ligands 
presented by CD1d.  Previous studies have suggested that the endogenous 
glycosphingolipid isoglobotrihexosylceramide (iGb3) is important for iNKT cell 
development and self-recognition (108).  Because a spontaneous increase in 
circulating lipids, as seen in apoE-/- mice, could affect the development of iNKT 
cells and subsequently lead to decreased peripheral numbers, we analyzed 
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thymic iNKT cells from apoE-/- and B6 mice by flow cytometry. Our data suggest 
that decreased iNKT cell numbers in apoE-/- mice are not the result of defects in 
thymic development because numbers and maturation markers of iNKT cells in 
the thymus remained largely unchanged.  Instead, our data support the 
hypothesis that the iNKT cell defect results from changes in the periphery.  This 
is in stark contrast to studies in mice with deficiencies in the Niemann-Pick type 
C1 and C2 proteins where reductions in iNKT cell numbers were observed in the 
thymus and peripheral lymphoid tissues (109-111).  This was also found to be 
the case in mouse models of other lysosomal lipid storage diseases such as 
mice deficient for  or galactosidase or hexosaminidases A and S (112).  
Therefore, decreased numbers of iNKT cells in the peripheral lymphoid organs of 
apoE-/- mice suggest that the endogenous glycolipids necessary to elicit normal 
selection of iNKT cells in the thymus are not affected by lipid accumulation.     
 Recent evidence has shown that B cell-mediated activation of iNKT cells 
is enhanced by apoE and is dependent upon the low density lipoprotein receptor 
(LDLr) (84). In addition, findings from Van den Elzen et al (83) have shown that 
circulating lipoproteins, such as very low density lipoproteins (VLDL), can 
enhance iNKT cell responses to glycolipid antigen presented by DCs. These 
experiments elegantly demonstrated that apoE may enhance glycolipid uptake, 
however, there was no evidence that glycolipid and apoE interact in vivo or that 
apoE was necessary for normal iNKT cell responses to exogenous lipid antigen. 
Although the absence of apoE and the effect this might have on antigen uptake is 
still an important consideration in our system, we have several pieces of 
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evidence suggesting that the absence of apoE alone cannot explain the 
difference in iNKT cell activation observed in hyperlipidemic mice.  First, DCs 
from apoE-/- mice are not compromised in their ability to present antigen to B6 
iNKT cells.  Additionally, CD1d loading of GGC and presentation on the cell 
surface, as measured by L363 antibody staining, was not compromised in apoE-/- 
DCs.  Therefore, we conclude that, although apoE may increase iNKT activation 
under normolipidemic conditions, the functional defects we observe in apoE-/- 
mice cannot be completely attributed to the lack of apoE.  
It has been shown previously in atherosclerosis studies that lipids such as 
the glycosphingolipid -glucosylceramide (-GlcCer) (113) and the 
disialoganglioside GD3 (114) accumulate in the serum of apoE-/- mice as well as 
in humans. In addition, natural activation of iNKT cells during microbial infection 
is often dependent on both IL-12 and presentation of endogenous glycolipid 
antigen by DCs (115). Thus, a possible explanation for the iNKT cell 
hyporesponsiveness we observe in apoE-/- mice is that these cells are chronically 
activated by increased levels of endogenous glycolipid.  Although, recent data 
from VanderLaan et al (78) suggest that endogenous iNKT antigen was not 
present in the serum of apoE-/- mice fed high fat diet, it is possible that presence 
of an endogenous ligand in tissue (such as in the liver, spleen or lymph node) 
and not serum is responsible for the changes in iNKT cells we observed.  
Alternatively, given that glycolipid antigens are processed and loaded onto CD1d 
within the APC after uptake, lysosomal accumulation of lipids during 
hyperlipidemia may play a role in the differences we observe. Supporting this 
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possibilty, a recent study from Bai et al (116), shows that lipid exchange within 
the lysosome is regulated by lipid structure as well as acidic lysosomal pH. 
However, our results indicate that DCs from apoE-/- mice retain their ability to 
activate iNKT cells, suggesting that the iNKT cell hyporesponsiveness in apoE-/- 
mice is due to chronic activation rather than defective antigen presentation. 
 Previous studies have shown that repeated activation of conventional T 
cells, such as in chronic viral infection, results in T cell exhaustion (117). 
Similarly, repeated activation of iNKT cells by -GalCer also results in a 
functionally unresponsive anergic phenotype (96). Our data show that apoE-/- 
iNKT cells display a phenotype similar to those rendered anergic due to repeated 
activation. This evidence supports our hypothesis that spontaneous dyslipidemia, 
as observed in apoE-/- mice, leads to chronic activation of iNKT cells.  Several 
recent reports have shown that the inhibitory receptor PD-1 is upregulated on 
exhausted T cells due to chronic activation (118, 119). In addition, PD-1 has 
been implicated in the induction and maintenance of iNKT cell anergy (102). In a 
recent study by Parekh et al (103), it was shown that blocking PD-1/PD-L 
interactions could prevent iNKT cell anergy, but could not overcome anergy once 
established. Our study illustrates that hyperlipidemic apoE-/- mice have 
spontaneously increased PD-1 expression on iNKT cells, although blocking PD-1 
in vitro was not able to restore responsiveness to -GalCer stimulation. 
Consistent with our data, recent clinical findings in HIV-infected humans 
indicated that these patients have increased PD-1 expression on iNKT cells, and 
PD-1 blockade did not restore iNKT cell function (36). Taken together, these data 
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suggest that in our system, decreased functionality of chronically activated iNKT 
cells is not dependent on PD-1 expression and may be irreversible once 
established. 
 It is known that iNKT cells become undetectable with tetramer soon after 
in vivo stimulation with -GalCer due to surface TCR downregulation (99). Our 
flow cytometry analyses demonstrate that there is a significant increase in the 
intracellular TCRin the apoE-/- mice as compared to B6 mice. Importantly, these 
studies were performed ex vivo without exogenous stimulation. In addition, we 
have shown that hyperlipidemic apoE-/- mice have modest but significant 
increases in myristic acid (14:0) and palmitic acid (16:0) (Figure 14).  Although, 
the physiologic relevance of this increase is not tested in the current study, the 
serum concentrations we observe are in excess of fatty acids concentrations that 
have been shown to activate APCs through Toll-like receptor activation (120).  
Therefore, it is possible that saturated fatty acid signaling in DCs via Toll-like 
receptor 4 leads to the production of IL-12, thus activating iNKT cells by the 
alternative or indirect pathway (62). Collectively, these data support the 
hypothesis that the hyperlipidemic environment of the apoE-/- mice spontaneously 
activates the iNKT cells, rendering them unresponsive to further stimulation.  
Further studies to test this hypothesis are warranted. 
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 In summary, our results indicate that an increase in circulating lipids leads 
to decreased iNKT cell functionality and that this dyslipidemia-associated 
decrease is iNKT cell intrinsic. The functional characteristics of iNKT cells are 
important to understand not only in chronic conditions of dyslipidemia, such as 
atherosclerosis, but also in diseases for which therapeutic approaches involving 
manipulation of iNKT cells are being considered. In addition, given that similar 
decreases in iNKT cell numbers and functions are observed in wild-type mice fed 
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Figure 14. apoE
-/-
 mice are dyslipidemic. Serum cholesterol (upper left panel) and 
triglyceride (upper right panel) of male B6 and apoE
-/-
 mice (≥16 weeks old) was determined 
by standard colorimetric assay. Free fatty acid (FFA) composition (lower panels) of serum 
from B6 and apoE
-/-
 mice (16 weeks old) was determined by gas chromatography. (n=3 mice 
per group). *p<0.05 as determined by Student‟s t test. 
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a high fat diet (8), caution may be warranted in immunologic studies involving the 
use of lipid-laden diets and therapies that give rise to dyslipidemia.  
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CHAPTER III 
 
DYSLIPIDEMIA DIRECTLY AFFECTS INKT CELL ACTIVATION 
 
Introduction 
 
 Dyslipidemia has long been associated with human diseases such as 
atherosclerosis. It is well established that atherosclerosis is a chronic 
inflammatory disease involving both innate and adaptive immunity, and several 
reports have investigated the effects of increased circulating lipids on cells of the 
immune system. The effects of cholesterol on macrophage function are well 
known. It has also been suggested that DC function may be reduced or inhibited 
during conditions of hypercholesterolemia (121, 122), however recent evidence 
suggests these cells retain their antigen presentation function even when 
cholesterol loaded (35). In addition to these studies, recent attention has focused 
on the role of cellular cholesterol homeostasis on conventional T cell activation 
and proliferation. Bensinger et al. have reported that liver X receptors (LXR), 
whose target genes are involved in cholesterol and fatty acid metabolism, play an 
important role in lymphocyte function (123).   
 Although well characterized in other immune cells, the direct influence of 
increased circulating lipids on iNKT cells has not been extensively studied. Given 
that iNKT cells are unique cells of the immune system which recognize glycolipid 
antigens, and that these cells are currently being considered as therapeutic 
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targets for several human diseases, understanding how the lipid environment 
directly affects their activation is imperative. 
 Our previous data show that iNKT cell hyporesponsiveness observed in 
dyslipidemic apoE-/- mice is iNKT cell autonomous and is not due to defective 
antigen presentation. Because these data suggest that increased circulating 
lipids in apoE-/- mice can affect iNKT cell function without affecting antigen 
presentation, we hypothesized that chronic dyslipidemia directly renders iNKT 
cells unresponsive to exogenous glycolipid antigen stimulation through 
intracellular lipid accumulation. The influence of intracellular lipid on the control of 
iNKT cell immune responses has yet to be determined. In this study, we sought 
to determine the direct effects of increased lipids on iNKT cell activation. Our 
results suggest that iNKT cells are directly influenced by their lipid environment 
and that these lipid-mediated changes in iNKT cell functions are due to direct 
changes in iNKT cells rather than through indirect mechanisms via APCs. 
 
Methods 
 
Animals.  Male C57BL/6J (B6) and B6.129P2-Apoetm1Unc/J (apoE-/-) mice were 
originally purchased from Jackson Laboratories (Bar Harbor) and maintained in 
our colonies under pathogen-free conditions. ApoE-/- mice have been 
backcrossed to B6 mice for greater than 10 generations. V14 transgenic mice 
were previously described (124). Animals were fed standard chow diet ad libitum. 
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All animal studies were approved by the Institutional Animal Care and Use 
Committee of Vanderbilt University (Nashville, TN). 
 
Reagents. α-GalCer (KRN7000) was obtained from Diagnocine and reconstituted 
in PBS containing 5.6% sucrose, 0.75% L-histadine, and 0.5% polysorbate-20 
(Sigma Aldrich). GGC (PBS-18) was described previously (90). Fluorescently 
labeled tetrameric CD1d molecules loaded with α-GalCer (CD1d tetramers) were 
obtained from the National Institute of Allergy and Infectious Diseases (NIH 
tetramer facility). For the in vitro iNKT cell hybridoma assays, the DN32.D3 
hybridoma was kindly provided by Dr. Albert Bendelac (University of Chicago, 
IL). CFSE labeling kit was purchased from Invitrogen. Rabbit anti-ABCA1 and 
anti-LXR were purchased from Novus Biologicals, and filipin, LXR agonist 
GW3965, and mouse anti--actin were purchased from Sigma Aldrich. Purified 
LDL from human donors was kindly provided Dr. Jay Jerome (Vanderbilt 
University). LDL was heavily oxidized by adding 0.4% copper sulfate (Sigma) in 
PBS, incubated overnight, and reaction quenched by 1mM EDTA (Sigma).  
 
Flow cytometry. Single-cell suspensions of the spleen and liver were prepared, 
and stained with fluorescently-labeled monoclonal antibodies as described 
previously (95). Flow cytometry was performed using a MACSQuant Analyzer 
instrument (Miltenyi Biotec) and the data were analyzed using FCS Express 
software (De Novo Software). The iNKT cell population was defined as B220- 
TCRβint tetramer+. 
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Enrichment of iNKT cells. Liver iNKT cells were enriched as previously described 
(95). Briefly, livers were perfused with PBS, digested with type II collagenase 
(Sigma), and then pressed through a 70 µm cell strainer. To remove adherent 
APCs, two rounds of panning, 1 hour each, were performed. The enriched iNKT 
cells were co-cultured for 48 hours with -GalCer-loaded DCs.  
 
Adoptive transfer of purified iNKT cells. Splenic iNKT cells were isolated as 
previously described (95) and labeled with CFSE according to the manufacturer‟s 
protocol (Invitrogen). Recipient mice were sub-lethally irradiated (450 rads) using 
a cesium source and 106 CFSE-labeled iNKT cells were injected retro-orbitally. 
Mice were injected with 4 µg/mouse -GalCer 4 days following adoptive 
transfers, and sacrificed 3 days post injection.    
  
iNKT cell hybridoma assays. Cells were cultured 24 hours in complete RPMI 
medium containing either FBS, B6 mouse serum, or apoE-/- mouse serum (from 
mice >16 weeks of age). The following day CD11c+ dendritic cells were isolated 
from B6 spleens. Splenic DCs were isolated as described previously (95), loaded 
with 50 ng/ml -GalCer for 30 minutes at 37°, and co-cultured with the 
hybridomas for an additional 48 hours. iNKT cell hybridoma activation was 
assessed by IL-2 production in cell culture supernatants by ELISA. 
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ELISA.  Mouse IL-4, IFN-, and IL-2 were measured by standard sandwich 
ELISA according to the manufacturer‟s protocol (BD Pharmingen). 
 
Statistics. Statistical significance between two groups was determined using a 
Student‟s t test, and significance between multiple groups was determined using 
one-way ANOVA with Newman-Keuls multiple comparison test for post hoc 
analysis. A value of p<0.05 was considered statistically significant and all 
statistical analyses were performed using GraphPad Prism software. 
 
 
Results 
 
Increased circulating lipids in apoE-/- mice directly affect NKT cell 
activation. 
 To determine whether increased serum lipids in apoE-/- mice decreases 
iNKT cell activation in vitro, the classical V14+ iNKT hybridoma (DN32.D3) were 
cultured 24 hours in complete RPMI medium containing either 10% FBS, B6 
mouse serum, or apoE-/- mouse serum. The following day, B6 splenic CD11c+ 
dendritic cells were isolated, loaded with 50 ng/ml -GalCer, and co-cultured with 
the hybridomas for an additional 48 hours. iNKT cell hybridoma activation was 
assessed by IL-2 production in cell culture supernatants. As shown in Figure 15, 
incubation with apoE-/- mouse serum reduces the activation of the iNKT cell 
hybridoma. Although these experiments were repeated multiple times, they did 
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not yield consistent results; however, these preliminary data are suggestive of a 
negative effect of lipid-laden apoE-/- mouse serum on iNKT cell activation in vitro, 
although further studies to confirm this are warranted.   
 
 
 
 
 
Lipid accumulation decreases iNKT cell activation.  
 To address whether iNKT cell responsiveness is directly affected by the 
increased circulating lipids, we tested iNKT cell hybridoma activation after oxLDL 
incubation in vitro. DN32.D3 hybridomas were incubated overnight in the 
presence or absence of 50 µg/ml oxLDL, then washed and co-cultured with -
GalCer-loaded (50 ng/ml) CD11c+ dendritic cells (purified from B6 spleens) for an 
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Figure 15. apoE
-/-
 mouse serum decreases iNKT cell hybridoma activation in vitro. 
iNKT hybridomas (DN32.D3) were cultured in complete RPMI containing 10% FBS, B6 
mouse serum, or apoE
-/-
 mouse serum for 24 hours, then co-cultured with -GalCer-
loaded B6 DCs for an additional 48 hours, and hybridoma activation, as determined by 
IL-2 production, was measured by ELISA. *p<0.05 as determined by one-way ANOVA. 
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additional 48 hours.  iNKT cell hybridoma activation, as determined by IL-2 
production, was measured by ELISA. As shown in Figure 16 (left panel), iNKT 
cell hybridoma activation is significantly decreased in cells loaded with oxLDL for 
24 hours, suggesting that lipid accumulation impairs the ability of iNKT cells to 
respond to glycolipid antigen. This decrease was not due to detrimental effects of 
oxLDL on the cells as indicated by no difference in percent viable cells (Figure 
16, right panel). Cell viability was determined after the removal of supernatant at 
the end of culture and calculated by trypan blue exclusion. 
 
 
 
 Given that LXRs are oxysterol sensing nuclear receptor important in 
reverse cholesterol transport, and have been shown to affect conventional T cell 
activation and proliferation (123), we tested whether activation of the LXR 
pathway in vitro affects iNKT cell activation. iNKT cell hybridomas (DN32.D3) 
were incubated for 24 hours in the presence of the synthetic LXR agonist 
 
 
Figure 16. oxLDL decreases iNKT cell hybridoma activation in vitro. The iNKT cell 
hybridoma DN32.D3 was incubated with 50 ug/ml oxLDL for 24 hours prior to co-culture 
with -GalCer-loaded B6 DCs (left panel) and the percentage of viable cells was 
determined by trypan blue exclusion (right panel).  *p<0.05 as determined by Student‟s t 
test. 
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GW3965 (2µM), then washed and co-cultured with -GalCer-loaded (50 ng/ml) 
CD11c+ dendritic cells (purified from B6 spleens) for an additional 48 hours.  
iNKT cell hybridoma activation, as determined by IL-2 production, was measured 
by ELISA (Figure 17A). These results show that activation of the LXR pathway 
decreases iNKT cell hybridoma responsiveness to exogenous glycolipid 
stimulation in vitro. 
 
 
 
 In addition, we examined LXR activation ex vivo using primary iNKT cells 
isolated from the spleen and liver of B6 and apoE-/- mice. The cells were purified 
by magnetic bead separation, then lysed and subjected to polyacrylamide gel 
electrophoresis. Western blot analysis was performed for detection of ABCA1 
expression, a downstream target of LXR activation. iNKT cell hybridomas 
incubated for 24 hours either in the presence of the LXR agonist GW3965 
 
Figure 17. LXR activation in iNKT cells. A, iNKT cell hybridomas DN32.D3 were incubated 
with 2 µM LXR agonist GW3965 for 24 prior to co-culture with -GalCer-loaded B6 DCs and 
hybridoma activation, as measured by IL-2 production, was determined after an additional 48 
hours by ELISA. B, The expression of ABCA1 in primary iNKT cells isolated from B6 and apoE
-/-
 
mice was determined by Western blot analyses (left panel). Quantification of the ABCA1 
Western blot (right panel). iNKT cell hybridomas cultured in the presence or absence of the LXR 
agonist GW3965 were used as positive and negative controls, respectively. *p<0.05 as 
determined by Student‟s t test. 
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(positive control) or DMSO (negative control) were used as controls for the 
expression of ABCA1 in this experiment. As shown in Figure 17B, ABCA1 is 
upregulated in primary iNKT cells from apoE-/- mice compared to B6, suggesting 
that activation of the LXR pathway is occurring in these cells.   
 
iNKT cells are capable of accumulating lipids in vitro and in vivo.   
 To determine whether iNKT cell lipid accumulation occurs in vitro, iNKT 
cell hybridomas were incubated 24 hours with complete medium containing BSA 
in the presence or absence of either 50 µg/ml oxLDL or native LDL. After 
incubation, the cells were washed, fixed with 2% paraformaldehyde, stained with 
12.5 µg/ml filipin, and analyzed by flow cytometry. Gating on live cells, the results 
are shown in Figure 18A. When compared to BSA only (MFI=13.48), the native 
LDL cultured cells (MFI=13.12) show no difference in filipin staining, however, the 
oxLDL cultured cells (MFI=20.22) have increased filipin staining, suggesting an 
increase in free cholesterol accumulation. 
 To determine whether iNKT cells accumulate lipids in vivo, we analyzed 
iNKT cells from spleens and livers of B6 and apoE-/- mice (age 16 weeks). After 
staining for surface markers, the cells were washed, fixed with 2% 
paraformaldehyde, stained with 12.5 µg/ml filipin, and analyzed by flow 
cytometry. Gating on TCR+Tetramer+B220- cells, the results for the filipin stain 
are shown in Figure 18B. These data indicate that there is no difference in 
splenic iNKT cell filipin staining (B6 MFI=8.48, apoE-/- MFI=9.57), however liver 
iNKT cells from apoE-/- mice have increased filipin staining (B6 MFI=5.59, apoE-/- 
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MFI=9.61), suggesting free cholesterol accumulation within membranes of these 
cells.   
 
 
 
 
 
 Furthermore, we analyzed B cells, dendritic cells, and conventional T cells 
from the spleens of these mice for cholesterol accumulation by filipin staining. As 
shown in Figure 18C, there is no difference in cholesterol staining of B cells,  
 
 
Figure18. iNKT cells are capable of free cholesterol accumulation. A, iNKT cell hybridomas 
were cultured in media containing BSA in the presence or absence of LDL or oxLDL for 24 
hours, and membrane cholesterol, as determined by filipin staining, was analyzed by flow 
cytometry. B, Spleen and liver iNKT cells from B6 (black line) and apoE
-/-
 (red line) mice were 
stained ex vivo with filipin and analyzed by flow cytometry. C, Splenic B cells (CD19
+
), DCs 
(CD11c
+
), and T cells (TCR
+
) were stained ex vivo with filipin and analyzed by flow cytometry.  
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DCs, or T cells from apoE-/- mice as compared to B6, suggesting that the 
hyperlipidemic environment directly affects the iNKT cell population specifically.   
 
Changes in iNKT cell activation in hyperlipidemic apoE-/- mice are not due 
to accumulation of an endogenous ligand.    
 To determine whether an endogenous ligand within apoE-/- mice is 
responsible for the changes observed in iNKT cell activation, we performed 
adoptive transfer studies to analyze iNKT cell proliferation. Thymic iNKT cells 
were purified from V14 transgenic B6 mice by magnetic bead separation, then 
labeled with CFSE, and injected into sub-lethally irradiated B6 and apoE-/- mice 
(12 weeks of age). After 7 days, the mice were sacrificed and iNKT cell 
proliferation was determined by flow cytometry. As positive controls, B6 mice 
which had been adoptively transferred were injected with -GalCer 3 days prior 
to sacrifice to induce iNKT cell proliferation. As shown in Figure 19, there was no 
difference in proliferation of B6 iNKT cells adoptively transferred into B6 and 
apoE-/- mice, as determined by CFSE dilution. These data suggest that within the 
hyperlipidemic environment of the apoE-/- mice, wild type iNKT cells are not being 
activated by an endogenous glycolipid antigen within the duration of these 
experiments. It is possible, however, that the hyperlipidemic environment may 
require longer than 7 days to exert pronounced effects upon iNKT cells, although 
this has yet to be determined.   
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Effects of dyslipidemia on iNKT cells may be irreversible once established. 
 Given that dyslipidemia seems to directly affect iNKT cells by rendering 
them hyporesponsive, we examined the possibility that placing these cells into a 
normo-lipidemic environment could restore iNKT function. To address this 
possibility, we adoptively transferred CFSE-labeled splenic iNKT cells from apoE-
deficient V14 transgenic mice (age 20 weeks) into age matched B6 and apoE-/- 
mice. Four days after the transfer, the mice were injected with -GalCer to 
stimulate iNKT cell proliferation and sacrificed 3 days later. iNKT cell replication 
cycles were determined by CFSE dilution as measured by flow cytometry. As 
 
 
Figure 19. Adoptive transfer of B6 iNKT cells into B6 and apoE
-/-
 mice. Thymic iNKT 
cells were purified from V14 transgenic B6 mice, labeled with CFSE, and adoptively 
transferred into B6 and apoE
-/-
 mice. Four days after transfer, mice were injected with 
vehicle (top panels) or -GalCer (bottom panels) and mice were sacrificed 3 days post 
injection. iNKT cell proliferation, as determined by CFSE dilution, was assessed by flow 
cytometry in the (A) spleen and (B) liver of recipient mice.  
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shown in Figure 20, compared to apoE-/- mice, the iNKT cells within the 
normolipidemic B6 mice do not display an increase in proliferation. Although 
representative of one experiment, these preliminary data suggest that once the 
negative effects of hyperlipidemia are exerted on iNKT cell responsiveness, 
these effects may be irreversible by correcting lipid homeostasis alone.    
 
 
 
 
 
 
 
 
Figure 20. Transfer of iNKT cells from hyperlipidemic mice into wild-type mice 
does not increase proliferation. Splenic iNKT cells were purified from V14 
transgenic apoE
-/-
 mice, labeled with CFSE, and adoptively transferred into B6 and 
apoE
-/-
 mice. Four days after transfer, mice were injected with vehicle (top panels) or -
GalCer (bottom panels) and mice were sacrificed 3 days post injection. iNKT cell 
proliferation, as determined by CFSE dilution, was assessed by flow cytometry in the 
(A) spleen and (B) liver of recipient mice.   
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Discussion 
   
 It is well established that increased lipid accumulation is associated with 
human diseases such as atherosclerosis. Increasing evidence also supports the 
role of inflammation and immunity in the pathogenesis of this disease. Several 
cells of the immune system, including macrophages, NK cells, mast cells, and 
dendritic cells, have been shown to play a role in atherosclerotic lesion 
progression (35, 36). Additionally, numerous studies have focused on 
macrophages in cardiovascular disease from their role as cells important in 
cholesterol homeostasis and scavenging modified lipoproteins and apoptotic 
cells (37), to their role as mediating inflammatory responses. In fact, direct effects 
of lipid accumulation within these cells have been well characterized. However, 
intrinsic effects of increased circulating lipids on iNKT cell activation are not 
known. Our data provide novel evidence that iNKT cells are directly affected by 
increased circulating lipids.  
 The direct effects of increased circulating lipids on particular cells of the 
immune system have been well characterized. It is well established that 
macrophage foam cells can form upon accumulation of cholesterol, a process 
which is primarily mediated by scavenger receptors (125). Previous studies 
involving atherosclerosis have shown that lipids, such as the glycosphingolipid -
glucosylceramide (-GlcCer) (113) and the disialoganglioside GD3 (114), 
accumulate within the serum of both humans and apoE-/- mice.  Therefore, a 
possible explanation for the iNKT cell hyporesponsiveness we observe in 
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hyperlipidemic apoE-/- mice is that these cells are spontaneously activated by 
increased levels of endogenous glycolipid.  However, given that we did not 
observe an increase in iNKT cell proliferation, our adoptive transfer studies of B6 
iNKT cells into apoE-/- mice suggest that there is not an accumulation of 
endogenous glycolipid antigen within the apoE-/- mice. 
 Previous studies have suggested that hyperlipidemia directly affects DCs, 
specifically by reducing their migratory capabilities (121), or inhibiting their 
activation (122). In contrast to these findings, our previously published data 
indicate that DCs from hyperlipidemic apoE-/- mice retain their ability to present 
antigens. Furthermore, the results from our ex vivo filipin staining indicate that 
spontaneous hyperlipidemia in apoE-/- mice does not result in free cholesterol 
accumulation within DCs in our model.  In addition, a recent study by Packard et 
al (35), showed that DCs within a hypercholesterolemic environment fully retain 
their antigen presentation capability, even when cholesterol loaded, further 
supporting the our hypothesis that increased circulating lipids directly affect iNKT 
cells rather than through indirect mechanisms via APCs. 
Recent attention has also focused on the influence of lipid metabolism on 
conventional T cell activation and proliferation. In a recent study by Bensinger et 
al (123), it was shown that transcriptional regulation of intracellular cholesterol 
homeostasis impacts the immune response by T cells. Specifically, LXR is an 
intrinsic regulator of lymphocyte proliferation, and sustained LXR signaling 
inhibits proliferation of T cells. In addition to LXR, another molecule involved in 
cholesterol efflux, apolipoprotein A-1 (apoA-1), has been shown to play a role in 
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T cell proliferation. ApoA-1-/-LDLr-/- mice fed a high fat diet display decreased T 
cell proliferation and activation, as well as develop features of autoimmunity 
(126).  
 Our previous data show that iNKT cells from hyperlipidemic apoE-/- mice 
have an impaired ability to respond to exogenous antigen stimulation and this 
hyporesponsiveness is not due to defective antigen presentation. Here we have 
shown that activation of the LXR pathway in vitro results in decreased iNKT cell 
hybridoma activation. Additionally, we observed spontaneous upregulation of 
ABCA1 in iNKT cells from apoE-/- mice, suggesting activation of the LXR pathway 
within these cells in vivo. Taken together, these studies suggest that cholesterol 
efflux via LXR-regulated ABC transporters potentially plays a suppressive role in 
iNKT cell activation. These data provide novel insight into the mechanism by 
which iNKT cells are hyporesponsive to exogenous stimulation in our model of 
spontaneous hyperlipidemia. Our results indicate that iNKT cells exhibit an 
impaired ability to respond to exogenous glycolipid antigen stimulation within a 
dyslipidemic environment. Therefore, the effects of lipid accumulation should be 
taken into consideration when designing future therapies manipulating iNKT 
cells.  
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CHAPTER IV 
 
ROLE OF LRP IN INKT CELL ACTIVATION 
 
Introduction 
 
 A recent study has shown that the low density lipoprotein receptor (LDLr) 
may be involved in the uptake of glycolipid antigen and enhance the activation of 
iNKT cells (83). However, because LDLr is sterol-sensitive and is downregulated 
with increased cellular cholesterol levels, this seems a limiting and inefficient 
means of antigen presentation. Another member of the LDLr gene family, the low 
density lipoprotein receptor-related protein (LRP) has vital structural resemblance 
to the LDLr and recognizes a wide array of diverse ligands, including apoE-
enriched lipoproteins and chylomicrons.  
 In addition to its role in lipoprotein metabolism, LRP has been shown to 
enhance antigen uptake within monocytes and macrophages (87) and is involved 
in control of cellular entry of bacterial toxins and viruses (88). The primary 
functions of LRP include lipoprotein transport, cell surface protease activity, and 
cellular uptake and lysosomal delivery of secreted prosaposins, saposin 
precursors (86). Importantly, saposins are required for the lysosomal loading and 
unloading of lipids onto CD1d (127), the molecule responsible for lipid antigen 
presentation to iNKT cells. Molecules bound to LRP are internalized and 
delivered to the lysosomes for subsequent degradation.  
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 The role of LRP in lipoprotein metabolism has been well characterized, 
however its role in iNKT cell activation is not known. Given that LRP binds 
bacteria and viruses and is essential for recapture of saposin precursors, we 
hypothesized that LRP plays a role in glycolipid antigen uptake and subsequent 
iNKT cell activation. In the current study, we addressed the role of LRP in iNKT 
cell activation and found mice lacking LRP on granulocytes, such as dendritic 
cells and macrophages, have reduced iNKT cell-mediated cytokine production, 
specifically IL-4, in response to exogenous glycolipid antigen stimulation. These 
data suggest that not only does LRP on APCs play a role in iNKT cell activation, 
it may also preferentially modulate iNKT cell cytokine production. 
 
Methods 
 
Animals. Male C57BL/6J (B6) and B6.129P2-Apoetm1Unc/J (apoE-/-) mice were 
originally purchased from Jackson Laboratories (Bar Harbor) and maintained in 
our colonies under pathogen-free conditions. LRPfl/flLyzMCre+ mice and human 
apoE-expressing transgenic (apoE2, apoE3, and apoE4) mice were kindly 
provided by Dr. Sergio Fazio (Vanderbilt University). Animals were fed standard 
chow diet ad libitum. All animal studies were approved by the Institutional Animal 
Care and Use Committee of Vanderbilt University (Nashville, TN). 
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Reagents. α-GalCer (KRN7000) was obtained from Diagnocine and reconstituted 
in PBS containing 5.6% sucrose, 0.75% L-histadine, and 0.5% polysorbate-20 
(Sigma Aldrich). GGC (PBS-18) was described previously (90). Fluorescently 
labeled tetrameric CD1d molecules loaded with α-GalCer (CD1d tetramers) were 
obtained from the National Institute of Allergy and Infectious Diseases (NIH 
tetramer facility). Anti-rabbit LRP antibody was kindly provided by Joachim Herz 
(University of Texas Southwestern). For the in vitro iNKT cell hybridoma assays, 
the N38-2C12 hybridoma was kindly provided by Dr. Albert Bendelac (University 
of Chicago, IL) 
 
Flow cytometry. Single-cell suspensions of the spleen and liver were prepared, 
and stained with fluorescently-labeled monoclonal antibodies as described 
previously (95). Flow cytometry was performed using a FACSCaliber machine 
BD Biosciences) and the data were analyzed using FCS Express software (De 
Novo Software). All fluorescently labeled antibodies used for flow cytometry were 
purchased from BD Biosciences. 
 
iNKT cell hybridoma assays. Cells were cultured 24 hours in complete RPMI 
medium containing FBS (Sigma). Bone marrow-derived DCs were isolated and 
cultured as previously described (97), loaded with 50 ng/ml -GalCer for 30 
minutes at 37°, and co-cultured with the hybridomas for an additional 48 hours. 
iNKT cell hybridoma activation was assessed by IL-2 production in cell culture 
supernatants by ELISA. 
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ELISA.  Mouse IL-4, IFN-, IL-2, and IgE were measured by standard sandwich 
ELISA according to the manufacturer‟s protocol (BD Pharmingen). 
 
 
Statistics. Statistical significance between two groups was determined using a 
Student‟s t test, and significance between multiple groups was determined using 
one-way ANOVA with Newman-Keuls multiple comparison test for post hoc 
analysis. A value of p<0.05 was considered statistically significant and all 
statistical analyses were performed using GraphPad Prism software. 
 
 
Results 
 
Cell specific LRP deletion 
 To determine the importance of LRP in iNKT cell activation, we used a 
mouse model with a granulocyte specific LRP deficiency (LRPfl/flLyzMCre+). This 
model utilizes Cre/lox recombination under the lysozyme M promoter and has 
previously been demonstrated to achieve >80% knockdown of LRP on 
granulocytes such as macrophages (128). The efficiency of LRP gene 
inactivation in bone marrow-derived DCs was determined by western blot (Figure 
21A). We observe a 90% decrease in LRP expression on BM-DCs derived from 
LRPfl/flLyzMCre+ mice compared to controls. Additionally, we examined LRP 
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expression on CD11c+ DCs in the spleen and observed decreased LRP on these 
cells. 
 
 
 
 
 To determine whether granulocyte specific knockdown of LRP affects 
iNKT cell numbers, splenocytes from age matched B6 and LRPfl/flLyzMCre+ mice 
were stained and analyzed by flow cytometry. There were no differences in iNKT 
cell percentages or absolute numbers (Figure 21B) between these groups of 
 
 
Figure 21. Analysis of BM-DCs and iNKTs in mice with a cell-specific knockdown of 
LRP. A, BM-DCs were isolated from B6, apoE
-/-
, and LRP
fl/fl
LyzMCre
+
 mice, and LRP 
expression was determined by Western blot (left panel). Western blot quantification shown in 
right panel. B, Percentages (left panel) and absolute numbers (right panel) of iNKT cells 
from the spleen of B6 and LRP
fl/fl
LyzMCre
+
 mice.    
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mice, indicating any differences we may observe in iNKT cell activation in 
LRPfl/flLyzMCre+  mice are not due to differences in iNKT cell numbers. 
 
Effect of LRP deficiency on antigen presentation 
 To determine the ability of LRPfl/flLyzMCre+ antigen presenting cells to 
activate iNKT cells in vitro, BM-DCs were isolated from these mice, pulsed with 
either α-GalCer or GGC (an α-GalCer precursor), and co-cultured with the 
autoreactive NKT hybridoma N382C12. After 48 hour incubation, the 
LRPfl/flLyzMCre+ BM-DCs displayed a significant decrease in their ability to 
activate the NKT hybridoma as measured by IL-2 production (Figure 22A). 
Importantly, because GGC requires lysosomal trafficking to be converted to its 
antigenic form α-GalCer (83), these data support a possible role for LRP in  
lysosomal trafficking of glycolipid antigen and subsequent surface presentation 
for iNKT cell activation. Given that a decrease in CD1d expression could be 
responsible for the decrease in iNKT cell hybridoma activation we observed, we 
analyzed CD1d expression on BM-DCs from LRPfl/flLyzMCre+ mice. As shown in 
Figure 22B, LRPfl/flLyzMCre+  BM-DCs have comparable CD1d expression to 
those from age matched B6 mice. 
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Absence of LRP skews iNKT cell cytokine production in response to 
exogenous stimulation  
 To determine the role of LRP in iNKT cell activation in vivo, we injected 
male age-matched LRPfl/flLyzMCre+ and B6 mice with 4µg α-GalCer i.p. per 
mouse. Serum was collected after 2 and 24 hours, and levels of IL-4 and IFN- 
were determined by ELISA. LRPfl/flLyzMCre+ mice have decreased IL-4 
production as compared to wild-type (Figure 23A). These data show that the 
absence of LRP biases the iNKT cells toward a Th1 response. To further 
 
 
Figure 22. In vitro iNKT cell hybridoma activation by LRP
fl/fl
LyzMCre
+ 
BM-DCs. A, 
BM-DCs isolated from B6 and LRP
fl/fl
LyzMCre
+ 
mice were loaded in vitro with -GalCer 
(left panel) or GGC (right panel) then co-cultured with the iNKT cell hybridoma N382C12. 
iNKT cell activation after 48 hours, as measured by IL-2 production, was determined by 
ELISA. B, CD1d expression on BM-DCs was determined by flow cytometry. *p<0.05 as 
determined by Student‟s t test.   
* 
* 
* 
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investigate the differences in cytokine production, we examined trans-activation 
of other spleen cell populations by flow cytometry 24 hours post α-GalCer 
injection. Our results show that LRPfl/flLyzMCre+ mice have decreased B and T 
cell activation compared to wild-type (Figure 22B). We also observed a decrease 
in IgE antibody production in the serum of LRPfl/flLyzMCre+ mice as determined 
by ELISA (Figure 22C). Given that IL-4 is a major switch factor for IgE production 
in mice (129), the decrease observed is consistent with decreased IL-4 
production.  
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 Finally, to indirectly examine a possible role for the apoE-LRP axis in iNKT 
cell activation, we used transgenic mice expressing human apoE isoforms from 
monocytes (130).  Human apoE exists as three isoforms (apoE2, apoE3, and 
apoE4). ApoE3 and apoE4 are recognized by the LDLr while apoE2 preferentially 
binds to LRP but not the LDLr. ApoE3, E4 and E2 transgenic mice (on the apoE-/- 
background), apoE-/- and B6 mice, were injected i.p. with 4µg α-GalCer, and 
serum levels of IL-4 and IFN- were measured by ELISA at 2 hours and 24 hours 
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Figure 23.LRP
fl/fl
LyzMCre
+
 mice have altered IL-4 production. A, B6 and LRP mice were 
injected with 4 µg -GalCer/mouse and serum IL-4 (left panel) and IFN- (right panel) were 
measured at 2 hours and 24 hours post injection, respectively. B, B6 and LRP mice were 
injected with 4 µg -GalCer/mouse and splenocytes were analyzed for activation by flow 
cytometry 24 hours post injection. C, Serum IgE titers were measured by ELISA 9 days post 
injection. *p<0.05 as determined by Student‟s t test.  
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respectively post injection. Compared to apoE3, the apoE2-expressing mice 
have a significant decrease in serum IFN- with no difference in serum IL-4 
(Figure 24), further supporting our data suggesting that not only does the LRP 
play a role in glycolipid uptake and iNKT cell activation, but that this receptor also 
modulates the quality of the iNKT cell response. 
  
 
 
 
 
Discussion 
 
 In this study, we have shown that LRP deficient BM-DCs have decreased 
NKT hybridoma activation in vitro, and that LRPfl/flLyzMCre+ mice have 
 
 
Figure 24. ApoE2 biases iNKT cells toward IL-4 production in vivo. B6 mice, apoE-/- 
mice, and mice transgenic for human apoE isoforms (apoE2, apoE3, and apoE4) were 
injected with 4ug a-GalCer/mouse. Serum IL-4 (left panel) was measured 2 hours post 
injection and IFN- (right panel) was measured 24 hours post injection. *p<0.05 as 
determined by Student‟s t test.  
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decreased IL-4 and IgE production, as well as decreased B and T cell activation, 
after NKT cell stimulation in vivo. These data suggest that LRP plays a role in 
NKT cell activation and modulation. 
 ApoE can be taken up by both LDLr and LRP, both of which are 
expressed on DCs. Recent evidence has implicated both apoE and the LDLr in 
the activation of iNKT cells via enhancing uptake of glycolipid antigen by DCs 
(83); however, the authors dismissed the ability of LRP to mediate lipid antigen 
uptake in their model. In that study, apoE2 (which binds to LRP exclusively) had 
a diminished ability to enhance CD1d-dependent responses compared to apoE3 
(which can bind to both LRP and LDLr); however these data were not shown. 
Additionally, their data show that exogenous addition of apoB (which binds to 
LDLr but not LRP) decreased antigen presentation compared to controls. 
However, in all of these studies, antigen presentation in LDLr-/- mice was shown 
to be reduced but not completely lost, suggesting that LRP could possibly still be 
involved in the uptake of apoE-antigen complexes. Another caveat is that IFN- 
production was the primary readout for iNKT activation. According to our data 
using LRPfl/flLyzMCre+ mice, iNKT cell-associated IFN- production remained 
largely unchanged compared to B6 mice, however we observed a significant 
reduction in IL-4 production indicating a potential role for LRP in altering the 
cytokine response in iNKT cells.  
 We have shown that LRP is involved in iNKT cell activation, indicating that 
the LDLr may not be the sole route of uptake of apoE-antigen complexes by 
APCs. Importantly, our results show that activation of iNKT cells through the LRP 
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pathway can skew their cytokine response. Given that targeted therapies 
involving iNKT cells are currently being considered in several human pathologies, 
further investigation to define a mechanism by which LRP modulates the quality 
of the iNKT cell response is warranted.  
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CHAPTER V 
 
DISCUSSION 
 
Summary 
 
 In summary, the data presented here support the hypothesis that chronic 
dyslipidemia results in decreased iNKT responsiveness through direct effects on 
iNKT cells. In apoE-/- mice, a model for spontaneous hyperlipidemia, we have 
shown that iNKT cell numbers and functions are significantly decreased 
compared to normolipidemic B6 mice. Importantly, these changes are not 
observed in young mice, before the onset of hyperlipidemia, suggesting that 
increased accumulation of circulating lipids over time negatively affects iNKT cell 
function. Additionally, our studies reveal that iNKT cells from hyperlipidemic 
apoE-/- mice exhibit an anergic phenotype, as determined by increased TCR 
internalization, as well as decreased proliferation and cytokine secretion in 
response to exogenous glycolipid stimulation. We have also shown that APCs 
from apoE-/- mice retain the ability to activate iNKT cells, therefore the defects we 
observed are iNKT cell intrinsic. 
 Furthermore, our data suggest that the increase in circulating lipids in 
apoE-/- mice results in decreased in iNKT cell function through direct effects on 
the iNKT cells. As determined by flow cytometry, liver iNKT cells from apoE-/- 
mice have an apparent increase in membrane free cholesterol accumulation as 
compared to those from B6 mice. Additionally, our in vitro studies indicate that 
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activation of the LXR pathway results in decreased activation of a classical iNKT 
cell hybridoma. Adoptive transfer of iNKT cells from hyperlipidemic apoE-/- mice 
into normolipidemic B6 mice does not increase the ability of these cells to 
proliferate, suggesting that the direct of effects of lipids on iNKT cells may be 
irreversible once established in our model.    
 
 
Overall Discussion 
 
  We have shown that iNKTs are directly influenced by their 
environment, and increased circulating lipids render them dysfunctional. In our 
studies, we have used a mouse model of spontaneous hyperlipidemia which 
leads to atherosclerosis. Consistent with this, Nakai et al. demonstrated that B6 
mice fed a high fat diet also have decreased iNKT cell numbers and functions 
(8). Taken together, these studies demonstrate that iNKT cells are extremely 
sensitive to their lipid environment. 
 Interestingly, we have consistently observed decreased iNKT cell 
responses in apoE-/- mice as these mice age and dyslipidemia continues. These 
data suggest that chronic hyperlipidemia, as observed in older (>12 weeks of 
age) apoE-/- mice, directly affects the ability of iNKT cells to respond to 
exogenous glycolipid antigen stimulation, given that iNKT cells from younger (<6 
weeks of age) apoE-/- mice display normal cytokine secretion in response to -
GalCer. These findings represent a novel role for the direct effects of increased 
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circulating lipids in iNKT cell activation. Although the mechanism by which 
increased cholesterol directly modulates iNKT cells has yet to be determined, 
studies utilizing human conventional T cells have suggested a possible link to the 
effect of cholesterol on TCR signaling via membrane stiffness (131). Previous 
studies have determined that compared to young subjects, T cell membranes are 
more rigid in elderly subjects, and that this increased stiffness is due to increased 
T cell free cholesterol content in the plasma membrane (132). Furthermore, when 
cholesterol content of the T cell membranes from young subjects was increased 
to the level observed in elderly subjects, there was a decrease in T cell 
proliferation and IL-2 secretion similar to that observed in immunosenescence 
(133). Additionally, Seres et al (134) have shown that in patients with 
hypercholesterolemia, peripheral blood lymphocytes display increased cellular 
cholesterol content within the plasma membrane. Although these studies were 
conducted using human subjects rather than mice, the results provide evidence 
that cholesterol can exert direct effects on the T lymphocyte population. 
Therefore, it is possible that increased free cholesterol within iNKT cell 
membranes represents a potential mechanism for the decreased iNKT cell 
responses observed in our model. 
 The effects of increased lipids on iNKT cells have not been extensively 
characterized and represent an important area of research which needs further 
study. Our data show decreased iNKT cell responsiveness to exogenous 
stimulation with glycolipid antigen within a hyperlipidemic environment. A recent 
study from Miyazaki et al investigated the ability of dietary lipids to modulate 
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iNKT cell responses (85). Using wild-type mice fed a high fat diet (HFD), they 
found decreased numbers of spleen and liver iNKT cells, and activation with -
GalCer results in suppression of IFN- but not IL-4 production. Although the 
mechanism for this skewed cytokine production was not determined in this study, 
the authors hypothesize that the decreased IFN- could be a result of altered 
antigen presentation, because they observed decreased CD1d expression on 
DCs from mice fed HFD. In our studies using apoE-/- mice fed a standard chow 
diet, we have shown a reduction in both IFN- and IL-4 production by iNKT cells, 
and that CD1d expression on DCs is not different compared to B6 mice, 
therefore this hypothesis may not pertain to our model. Discrepancies between 
these studies may be explained by the use of increased dietary lipids to induce 
hyperlipidemia as compared to spontaneously increased lipids as seen in our 
model. Because iNKT cells have been shown to play diverse roles in various 
disease models, these studies suggest that dyslipidemia may have grave impact 
on disease states. Taken together, these data provide evidence that a 
hyperlipidemic environment has a profound effect on iNKT cell activation and that 
molecules classically associated with lipid metabolism may regulate normal 
immune function.  
 
Role of iNKT cells in atherosclerosis  
 Our laboratory (7) and others (8, 9) have previously shown that iNKT cells 
are proatherogenic. Specifically, both apoE–/– and LDLr–/– mice lacking iNKT 
cells, as well as C57BL/6 mice fed a high-fat diet, have a significant reduction in 
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atherosclerotic lesion formation. In a study to determine the mechanism by which 
iNKT cells promote atherosclerosis, Aslanian et al (80) demonstrated that the 
role of iNKT cells in this disease is limited to early fatty streak formation. 
Additionally, activation of iNKT cells by -GalCer in vivo has been shown 
exacerbate atherosclerosis (7–9); however, a recent study by van Puijvelde et al 
(82) has shown that -GalCer injections had no effect on lesion size in  a model 
of carotid atherosclerosis using aged apoE-/- mice. Although their data were 
obtained using a model for carotid atherosclerosis, the results from van Puijvelde 
et al (82) could be explained by our data demonstrating that iNKT cells from aged 
apoE-/- mice display an anergic phenotype and are hyporesponsive to exogenous 
stimulation with -GalCer. Given that, by the time carotid atherosclerosis is 
initiated in their model, the iNKT cells in older apoE-/- mice are most likely 
rendered unresponsive to further activation by exogenous stimuli, we would 
hypothesize that -GalCer administration would have no effect on iNKT cell 
activation. 
    Provided that our goal was to determine the effect of the hyperlipidemic 
environment on iNKT cell function, and that our lab and others (7-9) have already 
established a proatherogenic role for iNKT cells, atherosclerosis data was not 
determined in the current study. However, because apoE-/- mice spontaneously 
develop atherosclerosis, we have proposed a model for the contribution of 
dyslipidemia to iNKT cell activation within the context of atherosclerosis (Figure 
25). iNKT cells are activated in apoE-/- mice at a young age when circulating 
lipids begin to spontaneously increase. This activation leads to the production of 
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proatherogenic cytokines such as IFN- and IL-4, therefore the normal iNKT 
responses we observe in young apoE-/- mice are potentially contributing to fatty 
streak formation in our model. Supporting this hypothesis, results from Aslanian 
et al (80) demonstrate that the role iNKT cells play in atherogenesis is limited to 
early fatty streak formation. As atherosclerosis-associated hyperlipidemia 
continues, we hypothesize that iNKT cells are repeatedly activated, therefore 
leading to an anergic phenotype. As atherosclerosis progresses in these mice, 
these cells are rendered dysfunctional possibly by a combination of repeated 
activation and the direct effects of increased cholesterol, and are no longer 
contributing to atherosclerotic lesion progression.  
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Figure 25. Model for iNKT cell function during spontaneous atherosclerosis in 
apoE
-/-
 mice. Spontaneous activation of iNKT cells occurs early in apoE
-/-
 mice as 
circulating lipids begin to increase (≥8 weeks of age). This activation results in the 
secretion of proatherogenic cytokines (IFN- and IL-4) by iNKT cells, therefore 
contributing to the development of early fatty streaks in these mice. As the 
atherosclerosis-associated dyslipidemia progresses (<12 weeks of age), iNKT cells 
become dysfunctional, presumably by repeated activation combined with direct effects 
of increased cholesterol on these cells. The resulting anergic iNKT cells no longer 
contribute to atherosclerotic lesion progression in these mice. 
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iNKT cells as therapeutic targets in human disease 
 Previous studies have shown that iNKT cells are important in anti-tumor 
immunity, and current human clinical trials utilizing iNKT cells are being 
developed for treatment of tumors. Specifically, activating iNKT cells using -
GalCer therapy has been shown to protect against some tumors (135, 136), and 
phase I/IIa clinical trials are being conducted on patients with advanced lung 
cancer (137). Because iNKT cells play an important role in the early development 
of atherosclerosis, these cells also potentially represent a target for the 
prevention of atherosclerosis. However, given our data shown here, in addition to 
the previously published data on the regulatory functions of iNKT cells on other 
cells of the immune system (138), we hypothesize that either targeting iNKT cells 
in the prevention of atherosclerosis or utilizing iNKT cells as a treatment for 
patients with this disease would not represent feasible or ideal options, given that 
the risks involved would outweigh the potential benefits. iNKT cells protect 
against microbial infections such as Listeria monocytogenes, Streptococcus 
pneumoniae, Leishmania major, Plasmodium berghei (139), as well as provide 
host protection against viral infections such as herpes simplex virus 1 (HSV-1) 
(140) and human immunodeficiency virus (HIV) (106). Additionally, iNKT cells 
prevent the development of several autoimmune diseases and maintain 
tolerance (141). The activation of iNKT cells with repeated -GalCer injections 
has been shown to protect against type 1 diabetes, experimental autoimmune 
encephalomyelitis (EAE), and RA in mice, but exacerbates lupus, 
atherosclerosis, and allergic airway inflammation (142). Because of their ability to 
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rapidly produce large amounts of cytokines and their involvement in several 
autoimmune diseases, iNKT cells are currently being considered as therapeutic 
targets in human disease. However, given the importance of iNKT cells in host 
protection against pathogens, maintenance of immune tolerance, and 
suppression of allergic airway inflammation, we hypothesize that manipulating 
these cells to prevent atherosclerosis development could potentially lead to 
increased susceptibility to infection, development of autoimmune disease, or 
increased allergic reactions.  
 Provided that therapies manipulating iNKT cells are being considered in 
human disease, understanding how iNKT cells are influenced by their 
environment is imperative. Therefore, we sought to determine the effects of 
atherosclerosis-associated dyslipidemia on iNKT cell function. Importantly, our 
data show that iNKT cells are hyporesponsive to exogenous stimulation by -
GalCer within the dyslipidemic environment of apoE-/- mice. These results 
contribute to our understanding of how iNKT cells function during conditions of 
increased circulating lipids, and suggest that the ability of dyslipidemia to render 
iNKT cells anergic should be taken into consideration when designing therapies 
using iNKT cells in diseases associated with an increased risk of cardiovascular 
disease such as type 1 diabetes (130), RA (131), and HIV infection (143). 
Additionally, our preliminary data suggesting that increased circulating 
cholesterol potentially exerts direct consequences on iNKT cell function 
represents an exciting, novel finding within the iNKT cell field.  
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 Future Directions 
 
 Future studies will be designed to determine the mechanism by which 
increased circulating lipids mediate iNKT cell dysfunction. One possible 
mechanism which we have yet to rule out involves the alternative or indirect 
pathway of iNKT cell activation (Figure 2). In this pathway, TLR-mediated 
activation of APCs leads to pro-inflammatory IL-12 cytokine production which, 
along with weak interaction of iNKT cells with endogenous antigens, activates 
iNKT cells. Although iNKT cell activation by this alternative pathway represents a 
potential mechanism in our model, we do not anticipate this to be the case; 
however, future experiments utilizing TLR4-/-apoE-/- mice and IL-12-/-apoE-/- mice 
will elucidate the contribution of the key molecules involved in this pathway.  
 Another mechanism by which a hyperlipidemic environment exerts direct 
effects on iNKT cell function, which is supported by data from our laboratory, is 
through intracellular lipid accumulation. Our data, although preliminary, provide 
novel insight into the direct effect of lipid accumulation on these immune cells. 
We have shown that iNKT cells from apoE-/- mice are capable of accumulating 
free cholesterol within their membranes, and that activation of the LXR pathway 
appears to be occurring in these cells in vivo, therefore, we anticipate this 
mechanism will be confirmed in our model. The next step in determining the 
importance of the mechanism by which increased cholesterol directly affects 
iNKT cells in our model will focus on the impact of increased membrane free 
cholesterol accumulation within iNKT cells on cytokine secretion by these cells.   
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 Lastly, another mechanism by which increased circulating lipids could 
influence iNKT cell activation may include the interaction of apoE and LRP. 
Although apoE has been shown to enhance lipid antigen uptake by APCs (83), 
our data suggest that the lack of apoE alone is not responsible for decreased 
iNKT cell responsiveness in our apoE-/- mouse model. However, the interplay 
between apoE and LRP may prove to be an interesting avenue to pursue in 
determining how iNKT cells are directly influenced by their lipid environment. 
Further investigations into this potential mechanism are currently being 
conducted in our laboratory.  
 In summary, we have shown the effects of dyslipidemia upon iNKT cell 
activation, and these results indicate that iNKT cells are directly influenced by 
their lipid environment. Given that iNKT cells are currently being considered as 
potential therapeutic targets in human pathologies, and that hyperlipidemia may 
have varying impacts within these different disease states, further investigations 
into the precise mechanism by which dyslipidemia affects iNKT cell functions are 
needed.  
   
90 
 
REFERENCES 
 
1. Epstein, S. E., J. Zhu, M. S. Burnett, Y. F. Zhou, G. Vercellotti, and D. Hajjar. 2000. 
Infection and atherosclerosis:  Potential roles of pathogen burden and molecular 
mimicry. Arterosclerosis, Thrombosis and Vascular Biology 20:1417. 
 
2. Farrugia, P. M., R. Lucariello, and J. T. Coppola. 2009. Human immunodeficiency virus 
and atherosclerosis. Cardiol Rev 17:211. 
 
3. Matsuura, E., K. Kobayashi, and L. R. Lopez. 2009. Atherosclerosis in autoimmune 
diseases. Curr Rheumatol Rep 11:61. 
 
4. Van Oosten, M., P. C. Rensen, E. S. Van Amersfoort, M. Van Eck, A. M. Van Dam, J. J. 
Breve, T. Vogel, A. Panet, T. J. Van Berkel, and J. Kuiper. 2001. Apolipoprotein E protects 
against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to 
treat gram-negative sepsis. J Biol Chem 276:8820. 
 
5. Hyka, N., J. M. Dayer, C. Modoux, T. Kohno, C. K. Edwards, 3rd, P. Roux-Lombard, and D. 
Burger. 2001. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor 
necrosis factor-alpha by blocking contact-mediated activation of monocytes by T 
lymphocytes. Blood 97:2381. 
 
6. Shimaoka, T., T. Nakayama, K. Hieshima, N. Kume, N. Fukumoto, M. Minami, K. 
Hayashida, T. Kita, O. Yoshie, and S. Yonehara. 2004. Chemokines generally exhibit 
scavenger receptor activity through their receptor-binding domain. J Biol Chem 
279:26807. 
 
7. Major, A. S., M. T. Wilson, J. L. McCaleb, Y. Ru Su, A. K. Stanic, S. Joyce, L. Van Kaer, S. 
Fazio, and M. F. Linton. 2004. Quantitative and qualitative differences in proatherogenic 
NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24:2351. 
 
8. Nakai, Y., K. Iwabuchi, S. Fujii, N. Ishimori, N. Dashtsoodol, K. Watano, T. Mishima, C. 
Iwabuchi, S. Tanaka, J. S. Bezbradica, T. Nakayama, M. Taniguchi, S. Miyake, T. 
Yamamura, A. Kitabatake, S. Joyce, L. Van Kaer, and K. Onoe. 2004. Natural Killer T Cells 
Accelerate Atherogenesis in Mice. Blood 104:2051. 
 
9. Tupin, E., A. Nicoletti, R. Elhage, M. Rudling, H. G. Ljunggren, G. K. Hansson, and G. P. 
Berne. 2004. CD1d-dependent Activation of NKT Cells Aggravates Atherosclerosis. J Exp 
Med 199:417. 
 
10. Glass, C., and J. Witzaum. 2001. Atheroscleroisis.  The road ahead. Cell 104:503. 
 
11. Stemme, S., B. Faber, J. Holm, O. Wiklund, J. L. Witztum, and G. K. Hansson. 1995. T 
lymphocytes from human atherosclerotic plaques recognize oxidized low density 
lipoprotein. Proc Natl Acad Sci U S A 92:3893. 
 
91 
 
12. Ait-Oufella, H., B. L. Salomon, S. Potteaux, A. K. Robertson, P. Gourdy, J. Zoll, R. Merval, 
B. Esposito, J. L. Cohen, S. Fisson, R. A. Flavell, G. K. Hansson, D. Klatzmann, A. Tedgui, 
and Z. Mallat. 2006. Natural regulatory T cells control the development of 
atherosclerosis in mice. Nat Med 12:178. 
 
13. Heller, E. A., E. Liu, A. M. Tager, Q. Yuan, A. Y. Lin, N. Ahluwalia, K. Jones, S. L. Koehn, V. 
M. Lok, E. Aikawa, K. J. Moore, A. D. Luster, and R. E. Gerszten. 2006. Chemokine CXCL10 
promotes atherogenesis by modulating the local balance of effector and regulatory T 
cells. Circulation 113:2301. 
 
14. Galkina, E., A. Kadl, J. Sanders, D. Varughese, I. J. Sarembock, and K. Ley. 2006. 
Lymphocyte recruitment into the aortic wall before and during development of 
atherosclerosis is partially L-selectin dependent. J Exp Med 203:1273. 
 
15. de Geest, B., and D. Collen. 2001. Antibodies against oxidized LDL for non-invasive 
diagnosis of atherosclerotic vascular disease. Eur Heart J 22:1517. 
 
16. Wu, J. T., and L. L. Wu. 1997. Autoantibodies against oxidized LDL. A potential marker 
for atherosclerosis. Clin Lab Med 17:595. 
 
17. Steinerova, A., J. Racek, F. Stozicky, T. Zima, L. Fialova, and A. Lapin. 2001. Antibodies 
against oxidized LDL--theory and clinical use. Physiol Res 50:131. 
 
18. Paiker, J. E., F. J. Raal, and M. von Arb. 2000. Auto-antibodies against oxidized LDL as a 
marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann 
Clin Biochem 37 ( Pt 2):174. 
 
19. Binder, C. J., S. Horkko, A. Dewan, M. K. Chang, E. P. Kieu, C. S. Goodyear, P. X. Shaw, W. 
Palinski, J. L. Witztum, and G. J. Silverman. 2003. Pneumococcal vaccination decreases 
atherosclerotic lesion formation: molecular mimicry between Streptococcus 
pneumoniae and oxidized LDL. Nat Med 9:736. 
 
20. Binder, C. J., K. Hartvigsen, M. K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. 
Corr, and J. L. Witztum. 2004. IL-5 links adaptive and natural immunity specific for 
epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114:427. 
 
21. Caligiuri, G., A. Nicoletti, B. Poirier, and G. K. Hansson. 2002. Protective immunity 
against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 
109:745. 
 
22. Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein 
(LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL 
reduces atherogenesis. Proc Natl Acad Sci U S A 92:821. 
 
23. Freigang, S., S. Horkko, E. Miller, J. L. Witztum, and W. Palinski. 1998. Immunization of 
LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL 
reduces progression of atherosclerosis by mechanisms other than induction of high 
titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18:1972. 
92 
 
24. Wick, G. 2000. Atherosclerosis--an autoimmune disease due to an immune reaction 
against heat-shock protein 60. Herz 25:87. 
 
25. Sherer, Y., A. Tenenbaum, S. Praprotnik, J. Shemesh, M. Blank, E. Z. Fisman, M. Motro, 
and Y. Shoenfeld. 2002. Autoantibodies to cardiolipin and beta-2-glycoprotein-I in 
coronary artery disease patients with and without hypertension. Cardiology 97:2. 
 
26. George, J., D. Harats, and Y. Shoenfeld. 2000. Autoimmunity in atherosclerosis. The role 
of autoantigens. Clin Rev Allergy Immunol 18:73. 
 
27. Shaw, P. X., S. Horkko, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. 
Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, 
apoptotic clearance, and protective immunity. J Clin Invest 105:1731. 
 
28. Palinski, W., S. Horkko, E. Miller, U. P. Steinbrecher, H. C. Powell, L. K. Curtiss, and J. L. 
Witztum. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized 
lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of 
oxidized low density lipoprotein in human plasma. J Clin Invest 98:800. 
 
29. Hasunuma, Y., E. Matsuura, Z. Makita, T. Katahira, S. Nishi, and T. Koike. 1997. 
Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively 
modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569. 
 
30. Afek, A., J. George, Y. Shoenfeld, B. Gilburd, Y. Levy, A. Shaish, P. Keren, Z. Janackovic, I. 
Goldberg, J. Kopolovic, and D. Harats. 1999. Enhancement of atherosclerosis in beta-2-
glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 67:19. 
 
31. George, J., A. Afek, B. Gilburd, M. Blank, Y. Levy, A. Aron-Maor, H. Levkovitz, A. Shaish, I. 
Goldberg, J. Kopolovic, D. Harats, and Y. Shoenfeld. 1998. Induction of early 
atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. 
Circulation 98:1108. 
 
32. Afek, A., J. George, B. Gilburd, L. Rauova, I. Goldberg, J. Kopolovic, D. Harats, and Y. 
Shoenfeld. 2000. Immunization of low-density lipoprotein receptor deficient (LDL-RD) 
mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 
14:115. 
 
33. Major, A. S., S. Fazio, and M. F. Linton. 2002. B-lymphocyte deficiency increases 
atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 22:1892. 
 
34. Andersson, J., P. Libby, and G. K. Hansson. Adaptive immunity and atherosclerosis. Clin 
Immunol 134:33. 
 
35. Packard, R. R., A. H. Lichtman, and P. Libby. 2009. Innate and adaptive immunity in 
atherosclerosis. Semin Immunopathol 31:5. 
 
36. Hartvigsen, K., C. J. Binder, L. F. Hansen, A. Rafia, J. Juliano, S. Horkko, D. Steinberg, W. 
Palinski, J. L. Witztum, and A. C. Li. 2007. A diet-induced hypercholesterolemic murine 
93 
 
model to study atherogenesis without obesity and metabolic syndrome. Arterioscler 
Thromb Vasc Biol 27:878. 
 
37. Tabas, I. 2007. Apoptosis and efferocytosis in mouse models of atherosclerosis. Curr 
Drug Targets 8:1288. 
 
38. Doherty, T. M., E. A. Fisher, and M. Arditi. 2006. TLR signaling and trapped vascular 
dendritic cells in the development of atherosclerosis. Trends Immunol 27:222. 
 
39. Monaco, C., S. M. Gregan, T. J. Navin, B. M. Foxwell, A. H. Davies, and M. Feldmann. 
2009. Toll-like receptor-2 mediates inflammation and matrix degradation in human 
atherosclerosis. Circulation 120:2462. 
 
40. Lee, J. G., E. J. Lim, D. W. Park, S. H. Lee, J. R. Kim, and S. H. Baek. 2008. A combination of 
Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal 20:2266. 
 
41. Bendelac, A., M. N. Rivera, S. H. Park, and J. H. Roark. 1997. Mouse CD1-specific NK1 T 
cells:  development , specificity, and function. Annual Review of Immunology 15:535. 
 
42. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells. Nature 
Reviews of Immunology 2:557. 
 
43. Gigli, G., S. Caielli, D. Cutuli, and M. Falcone. 2007. Innate immunity modulates 
autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth 
and function of regulatory invariant natural killer T cells through dendritic cell 
maturation. Immunology 122:409. 
 
44. Nowak, M., and J. Stein-Streilein. 2007. Invariant NKT cells and tolerance. Int Rev 
Immunol 26:95. 
 
45. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. 
Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice 
against experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 
194:1801. 
 
46. Wang, B., Y. B. Geng, and C. R. Wang. 2001. CD1-restricted NK T cells protect nonobese 
diabetic mice from developing diabetes. Journal of Experimental Medicine 194:313. 
 
47. Oishi, Y., T. Sumida, A. Sakamoto, Y. Kita, K. Kurasawa, Y. Nawata, K. Takabayashi, H. 
Takahashi, S. Yoshida, M. Taniguchi, Y. Saito, and I. Iwamoto. 2001. Selective reduction 
and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with 
disease activity in patients with systemic lupus erythematosus. J Rheumatol 28:275. 
 
48. Morita, M., K. Motoki, K. Akimoto, T. Natori, T. Sakai, E. Sawa, K. Yamaji, Y. Koezuka, E. 
Kobayashi, and H. Fukushima. 1995. Structure-activity relationship of alpha-
galactosylceramides against B16-bearing mice. J Med Chem 38:2176. 
 
94 
 
49. Tupin, E., Y. Kinjo, and M. Kronenberg. 2007. The unique role of natural killer T cells in 
the response to microorganisms. Nat Rev Microbiol 5:405. 
 
50. Wilson, M. T., A. K. Singh, and L. Van Kaer. 2002. Immunotherapy with ligands of natural 
killer T cells. Trends in Molecular Medicine 8:225. 
 
51. Yang, Y., M. Bao, and J. W. Yoon. 2001. Intrinsic defects in the T-cell lineage results in 
natural killer T-cell deficiency and the development of diabetes in the nonobese diabetic 
mouse. Diabetes 50:2691. 
 
52. Wu, D., G. W. Xing, M. A. Poles, A. Horowitz, Y. Kinjo, B. Sullivan, V. Bodmer-Narkevitch, 
O. Plettenburg, M. Kronenberg, M. Tsuji, D. D. Ho, and C. H. Wong. 2005. Bacterial 
glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S 
A 102:1351. 
 
53. Godfrey, D. I., and S. P. Berzins. 2007. Control points in NKT-cell development. Nat Rev 
Immunol 7:505. 
 
54. Gapin, L., J. L. Matsuda, C. D. Surh, and M. Kronenberg. 2001. NKT cells derive from 
double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2:971. 
 
55. Benlagha, K., T. Kyin, A. Beavis, L. Teyton, and A. Bendelac. 2002. A thymic precursor to 
the NK T cell lineage. Science 296:553. 
 
56. Pellicci, D. G., K. J. Hammond, A. P. Uldrich, A. G. Baxter, M. J. Smyth, and D. I. Godfrey. 
2002. A natural killer T (NKT) cell developmental pathway iInvolving a thymus-
dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med 195:835. 
 
57. McNab, F. W., D. G. Pellicci, K. Field, G. Besra, M. J. Smyth, D. I. Godfrey, and S. P. 
Berzins. 2007. Peripheral NK1.1 NKT cells are mature and functionally distinct from their 
thymic counterparts. J Immunol 179:6630. 
 
58. Brossay, L., D. Jullien, S. Cardell, B. C. Sydora, N. Burdin, R. L. Modlin, and M. 
Kronenberg. 1997. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J 
Immunol 159:1216. 
 
59. Kang, S. J., and P. Cresswell. 2004. Saposins facilitate CD1d-restricted presentation of an 
exogenous lipid antigen to T cells. Nat Immunol 5:175. 
 
60. Zhou, D., C. Cantu, 3rd, Y. Sagiv, N. Schrantz, A. B. Kulkarni, X. Qi, D. J. Mahuran, C. R. 
Morales, G. A. Grabowski, K. Benlagha, P. Savage, A. Bendelac, and L. Teyton. 2004. 
Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 
303:523. 
 
61. Zeng, Z., A. R. Castano, B. W. Segelke, E. A. Stura, P. A. Peterson, and I. A. Wilson. 1997. 
Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding 
groove. Science 277:339. 
95 
 
62. Van Kaer, L. 2007. NKT cells: T lymphocytes with innate effector functions. Curr Opin 
Immunol 19:354. 
 
63. Brigl, M., and M. B. Brenner. How invariant natural killer T cells respond to infection by 
recognizing microbial or endogenous lipid antigens. Semin Immunol 22:79. 
 
64. Kinjo, Y., E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. R. Benhnia, D. M. Zajonc, G. 
Ben-Menachem, G. D. Ainge, G. F. Painter, A. Khurana, K. Hoebe, S. M. Behar, B. Beutler, 
I. A. Wilson, M. Tsuji, T. J. Sellati, C. H. Wong, and M. Kronenberg. 2006. Natural killer T 
cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7:978. 
 
65. Olson, C. M., Jr., T. C. Bates, H. Izadi, J. D. Radolf, S. A. Huber, J. E. Boyson, and J. 
Anguita. 2009. Local production of IFN-gamma by invariant NKT cells modulates acute 
Lyme carditis. J Immunol 182:3728. 
 
66. Sriram, V., W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2005. Cell wall 
glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. 
Eur J Immunol 35:1692. 
 
67. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. 
Sato, E. Kondo, H. Koseki, and M. Taniguchi. 1997. CD1d-restricted and TCR-mediated 
activation of valpha14 NKT cells by glycosylceramides. Science 278:1626. 
 
68. Brutkiewicz, R. R., and V. Sriram. 2002. Natural killer T (NKT) cells and their role in 
antitumor immunity. Crit Rev Oncol Hematol 41:287. 
 
69. Brutkiewicz, R. R. 2006. CD1d ligands: the good, the bad, and the ugly. J Immunol 
177:769. 
 
70. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells 
in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119. 
 
71. Chung, Y., H. Qin, C. Y. Kang, S. Kim, L. W. Kwak, and C. Dong. 2007. An NKT-mediated 
autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. 
Blood 110:2013. 
 
72. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-
dependent NKT cells. J Clin Invest 114:1379. 
 
73. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents 
autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 
413:531. 
 
74. Wilson, S. B., S. C. Kent, K. T. Patton, T. Orban, R. A. Jackson, M. Exley, S. Porcelli, D. A. 
Schatz, M. A. Atkinson, S. P. Balk, J. L. Strominger, and D. A. Hafler. 1998. Extreme Th1 
bias of invariant Va24JaQ T cells in type 1 diabetes. Nature 391:177. 
96 
 
75. Gombert, J. M., A. Herbelin, E. Tancrede-Bohin, M. Dy, C. Carnaud, and J. F. Bach. 1996. 
Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. 
Eur J Immunol 26:2989. 
 
76. Bobryshev, Y. V., and R. S. Lord. 2005. Co-accumulation of dendritic cells and natural 
killer T cells within rupture-prone regions in human atherosclerotic plaques. J Histochem 
Cytochem 53:781. 
 
77. Chan, W. L., N. Pejnovic, H. Hamilton, T. V. Liew, D. Popadic, A. Poggi, and S. M. Khan. 
2005. Atherosclerotic abdominal aortic aneurysm and the interaction between 
autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper 
T cells. Circ Res 96:675. 
 
78. VanderLaan, P. A., C. A. Reardon, Y. Sagiv, L. Blachowicz, J. Lukens, M. Nissenbaum, C. R. 
Wang, and G. S. Getz. 2007. Characterization of the natural killer T-cell response in an 
adoptive transfer model of atherosclerosis. Am J Pathol 170:1100. 
 
79. Rogers, L., S. Burchat, J. Gage, M. Hasu, M. Thabet, L. Willcox, T. A. Ramsamy, and S. C. 
Whitman. 2008. Deficiency of invariant V alpha 14 natural killer T cells decreases 
atherosclerosis in LDL receptor null mice. Cardiovasc Res 78:167. 
 
80. Aslanian, A. M., H. A. Chapman, and I. F. Charo. 2004. Transient Role for CD1d-Restricted 
Natural Killer T Cells in the Formation of Atherosclerotic Lesions. Arterioscler Thromb 
Vasc Biol:01.ATV.0000153046.59370.13. 
 
81. To, K., A. Agrotis, G. Besra, A. Bobik, and B. H. Toh. 2009. NKT cell subsets mediate 
differential proatherogenic effects in ApoE-/- mice. Arterioscler Thromb Vasc Biol 
29:671. 
 
82. van Puijvelde, G. H., E. J. van Wanrooij, A. D. Hauer, P. de Vos, T. J. van Berkel, and J. 
Kuiper. 2009. Effect of natural killer T cell activation on the initiation of atherosclerosis. 
Thromb Haemost 102:223. 
 
83. van den Elzen, P., S. Garg, L. Leon, M. Brigl, E. A. Leadbetter, J. E. Gumperz, C. C. 
Dascher, T. Y. Cheng, F. M. Sacks, P. A. Illarionov, G. S. Besra, S. C. Kent, D. B. Moody, 
and M. B. Brenner. 2005. Apolipoprotein-mediated pathways of lipid antigen 
presentation. Nature 437:906. 
 
84. Allan, L. L., K. Hoefl, D. J. Zheng, B. K. Chung, F. K. Kozak, R. Tan, and P. van den Elzen. 
2009. Apolipoprotein mediated lipid antigen presentation in B cells provides a pathway 
for innate help by NKT cells. Blood. 
 
85. Miyazaki, Y., K. Iwabuchi, D. Iwata, A. Miyazaki, Y. Kon, M. Niino, S. Kikuchi, Y. Yanagawa, 
L. V. Kaer, H. Sasaki, and K. Onoe. 2008. Effect of high fat diet on NKT cell function and 
NKT cell-mediated regulation of Th1 responses. Scand J Immunol 67:230. 
 
86. Herz, J., and D. K. Strickland. 2001. LRP: a multifunctional scavenger and signaling 
receptor. J Clin Invest 108:779. 
97 
 
87. Chu, C. T., T. D. Oury, J. J. Enghild, and S. V. Pizzo. 1994. Adjuvant-free in vivo targeting. 
Antigen delivery by alpha 2-macroglobulin enhances antibody formation. J Immunol 
152:1538. 
 
88. Lillis, A. P., L. B. Van Duyn, J. E. Murphy-Ullrich, and D. K. Strickland. 2008. LDL receptor-
related protein 1: unique tissue-specific functions revealed by selective gene knockout 
studies. Physiol Rev 88:887. 
 
89. Wu, L., C. L. Gabriel, V. V. Parekh, and L. Van Kaer. 2009. Invariant natural killer T cells: 
innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73:535. 
 
90. Liu, Y., R. D. Goff, D. Zhou, J. Mattner, B. A. Sullivan, A. Khurana, C. Cantu, 3rd, E. V. 
Ravkov, C. C. Ibegbu, J. D. Altman, L. Teyton, A. Bendelac, and P. B. Savage. 2006. A 
modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J 
Immunol Methods 312:34. 
 
91. Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. 
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. 
Int Immunol 8:765. 
 
92. Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. 
Pardoll, K. Okumura, M. Azuma, and H. Yagita. 2002. Expression of programmed death 1 
ligands by murine T cells and APC. J Immunol 169:5538. 
 
93. Yu, K. O., J. S. Im, P. A. Illarionov, R. M. Ndonye, A. R. Howell, G. S. Besra, and S. A. 
Porcelli. 2007. Production and characterization of monoclonal antibodies against 
complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d. J 
Immunol Methods 323:11. 
 
94. Burdin, N., L. Brossay, Y. Koezuka, S. T. Smiley, M. J. Grusby, M. Gui, M. Taniguchi, K. 
Hayakawa, and M. Kronenberg. 1998. Selective ability of mouse CD1 to present 
glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T 
lymphocytes. J Immunol 161:3271. 
 
95. Kim, S., S. Lalani, V. V. Parekh, T. L. Vincent, L. Wu, and L. Van Kaer. 2008. Impact of 
bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in 
mice. J Clin Invest 118:2301. 
 
96. Parekh, V. V., M. T. Wilson, D. Olivares-Villagomez, A. K. Singh, L. Wu, C. R. Wang, S. 
Joyce, and L. Van Kaer. 2005. Glycolipid antigen induces long-term natural killer T cell 
anergy in mice. J Clin Invest 115:2572. 
 
97. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 
1999. An advanced culture method for generating large quantities of highly pure 
dendritic cells from mouse bone marrow. J Immunol Methods 223:77. 
 
98 
 
98. Takeda, K., Y. Hayakawa, L. Van Kaer, H. Matsuda, H. Yagita, and K. Okumura. 2000. 
Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc 
Natl Acad Sci U S A 97:5498. 
 
99. Braun, N., N. S. Wade, E. K. Wakeland, and A. S. Major. 2008. Accelerated 
atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-
susceptible LDLr(-/-) mice. Lupus 17:1070. 
 
100. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C.-R. Wang, 
S. Joyce, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid 
antigens in characterized by surface receptor down-modulation and expansion. 
Proceedings of the National Acadamy of Science USA 19:10913. 
 
101. Peng, G., S. Li, W. Wu, X. Tan, Y. Chen, and Z. Chen. 2008. PD-1 upregulation is 
associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol 
Immunol 45:963. 
 
102. Chang, W. S., J. Y. Kim, Y. J. Kim, Y. S. Kim, J. M. Lee, M. Azuma, H. Yagita, and C. Y. Kang. 
2008. Cutting edge: Programmed death-1/programmed death ligand 1 interaction 
regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 
181:6707. 
 
103. Parekh, V. V., S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L. Wu, and L. V. 
Kaer. 2009. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor 
activities of glycolipid-activated invariant NKT cells. J Immunol 182:2816. 
 
104. Motohashi, S., and T. Nakayama. 2008. Clinical applications of natural killer T cell-based 
immunotherapy for cancer. Cancer Sci 99:638. 
 
105. Fletcher, M. T., and A. G. Baxter. 2009. Clinical application of NKT cell biology in type I 
(autoimmune) diabetes mellitus. Immunol Cell Biol 87:315. 
 
106. Li, D., and X. N. Xu. 2008. NKT cells in HIV-1 infection. Cell Res 18:817. 
 
107. Cerundolo, V., J. D. Silk, S. H. Masri, and M. Salio. 2009. Harnessing invariant NKT cells in 
vaccination strategies. Nat Rev Immunol 9:28. 
 
108. Zhou, D., J. Mattner, C. Cantu, 3rd, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. 
Wu, T. Yamashita, S. Teneberg, D. Wang, R. L. Proia, S. B. Levery, P. B. Savage, L. Teyton, 
and A. Bendelac. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 
306:1786. 
 
109. Sagiv, Y., K. Hudspeth, J. Mattner, N. Schrantz, R. K. Stern, D. Zhou, P. B. Savage, L. 
Teyton, and A. Bendelac. 2006. Cutting edge: impaired glycosphingolipid trafficking and 
NKT cell development in mice lacking Niemann-Pick type C1 protein. J Immunol 177:26. 
 
99 
 
110. Schrantz, N., Y. Sagiv, Y. Liu, P. B. Savage, A. Bendelac, and L. Teyton. 2007. The 
Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules 
and contributes to the thymic selection of NKT cells. J Exp Med 204:841. 
 
111. Schumann, J., F. Facciotti, L. Panza, M. Michieletti, F. Compostella, A. Collmann, L. Mori, 
and G. De Libero. 2007. Differential alteration of lipid antigen presentation to NKT cells 
due to imbalances in lipid metabolism. Eur J Immunol 37:1431. 
 
112. Gadola, S. D., J. D. Silk, A. Jeans, P. A. Illarionov, M. Salio, G. S. Besra, R. Dwek, T. D. 
Butters, F. M. Platt, and V. Cerundolo. 2006. Impaired selection of invariant natural killer 
T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp 
Med 203:2293. 
 
113. Garner, B., D. A. Priestman, R. Stocker, D. J. Harvey, T. D. Butters, and F. M. Platt. 2002. 
Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene 
knockout mice. J Lipid Res 43:205. 
 
114. Wu, D. Y., N. H. Segal, S. Sidobre, M. Kronenberg, and P. B. Chapman. 2003. Cross-
presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198:173. 
 
115. Brigl, M., L. Bry, S. C. Kent, J. E. Gumperz, and M. B. Brenner. 2003. Mechanism of CD1d-
restricted natural killer T cell activation during microbial infection. Nat Immunol 4:1230. 
 
116. Bai, L., Y. Sagiv, Y. Liu, S. Freigang, K. O. Yu, L. Teyton, S. A. Porcelli, P. B. Savage, and A. 
Bendelac. 2009. Lysosomal recycling terminates CD1d-mediated presentation of short 
and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer. Proc Natl Acad 
Sci U S A 106:10254. 
 
117. Wherry, E. J., S. J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. 
N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell 
exhaustion during chronic viral infection. Immunity 27:670. 
 
118. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. 
Mackey, J. D. Miller, A. J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. 
Eichbaum, M. Altfeld, E. J. Wherry, H. M. Coovadia, P. J. Goulder, P. Klenerman, R. 
Ahmed, G. J. Freeman, and B. D. Walker. 2006. PD-1 expression on HIV-specific T cells is 
associated with T-cell exhaustion and disease progression. Nature 443:350. 
 
119. Trautmann, L., L. Janbazian, N. Chomont, E. A. Said, S. Gimmig, B. Bessette, M. R. 
Boulassel, E. Delwart, H. Sepulveda, R. S. Balderas, J. P. Routy, E. K. Haddad, and R. P. 
Sekaly. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to 
reversible immune dysfunction. Nat Med 12:1198. 
 
120. Weatherill, A. R., J. Y. Lee, L. Zhao, D. G. Lemay, H. S. Youn, and D. H. Hwang. 2005. 
Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions 
mediated through TLR4. J Immunol 174:5390. 
100 
 
121. Angeli, V., J. Llodra, J. X. Rong, K. Satoh, S. Ishii, T. Shimizu, E. A. Fisher, and G. J. 
Randolph. 2004. Dyslipidemia associated with atherosclerotic disease systemically alters 
dendritic cell mobilization. Immunity 21:561. 
 
122. Shamshiev, A. T., F. Ampenberger, B. Ernst, L. Rohrer, B. J. Marsland, and M. Kopf. 2007. 
Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative 
dendritic cells and protective Th1 type immunity. J Exp Med 204:441. 
 
123. Bensinger, S. J., M. N. Bradley, S. B. Joseph, N. Zelcer, E. M. Janssen, M. A. Hausner, R. 
Shih, J. S. Parks, P. A. Edwards, B. D. Jamieson, and P. Tontonoz. 2008. LXR signaling 
couples sterol metabolism to proliferation in the acquired immune response. Cell 
134:97. 
 
124. Bendelac, A., R. D. Hunziker, and O. Lantz. 1996. Increased interleukin 4 and 
immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med 
184:1285. 
 
125. Greaves, D. R., and S. Gordon. 2005. Thematic review series: the immune system and 
atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J 
Lipid Res 46:11. 
 
126. Wilhelm, A. J., M. Zabalawi, J. M. Grayson, A. E. Weant, A. S. Major, J. Owen, M. 
Bharadwaj, R. Walzem, L. Chan, K. Oka, M. J. Thomas, and M. G. Sorci-Thomas. 2009. 
Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and 
autoimmunity. Arterioscler Thromb Vasc Biol 29:843. 
 
127. Yuan, W., X. Qi, P. Tsang, S. J. Kang, P. A. Illarionov, G. S. Besra, J. Gumperz, and P. 
Cresswell. 2007. Saposin B is the dominant saposin that facilitates lipid binding to 
human CD1d molecules. Proc Natl Acad Sci U S A 104:5551. 
 
128. Overton, C. D., P. G. Yancey, A. S. Major, M. F. Linton, and S. Fazio. 2007. Deletion of 
macrophage LDL receptor-related protein increases atherogenesis in the mouse. Circ 
Res 100:670. 
 
129. Yoshimoto, T., A. Bendelac, J. Hu-Li, and W. E. Paul. 1995. Defective IgE production by 
SJL mice is linked to the absence of CD4+, Nk1.1+ T cells that promptly  produce 
interluekin 4. Proceedings of the National Acadamy of Science USA 92:11931. 
 
130. Fan, D., S. Qiu, C. D. Overton, P. G. Yancey, L. L. Swift, W. G. Jerome, M. F. Linton, and S. 
Fazio. 2007. Impaired secretion of apolipoprotein E2 from macrophages. J Biol Chem 
282:13746. 
 
131. Tomoiu, A., A. Larbi, C. Fortin, G. Dupuis, and T. Fulop, Jr. 2007. Do membrane rafts 
contribute to human immunosenescence? Ann N Y Acad Sci 1100:98. 
 
132. Rivnay, B., S. Bergman, M. Shinitzky, and A. Globerson. 1980. Correlations between 
membrane viscosity, serum cholesterol, lymphocyte activation and aging in man. Mech 
Ageing Dev 12:119. 
101 
 
133. Fulop, T., Jr., N. Douziech, A. C. Goulet, S. Desgeorges, A. Linteau, G. Lacombe, and G. 
Dupuis. 2001. Cyclodextrin modulation of T lymphocyte signal transduction with aging. 
Mech Ageing Dev 122:1413. 
 
134. Seres, I., M. Freyss-Beguin, A. Mohacsi, B. Kozlovsky, J. Simon, M. A. Devynck, and T. 
Fulop, Jr. 1996. Alteration of lymphocyte membrane phospholipids and intracellular free 
calcium concentrations in hyperlipidemic subjects. Atherosclerosis 121:175. 
 
135. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. 
Scheper, H. J. van der Vliet, A. J. van den Eertwegh, M. Roelvink, J. Beijnen, H. Zwierzina, 
and H. M. Pinedo. 2002. A phase I study of the natural killer T-cell ligand alpha-
galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702. 
 
136. Crul, M., R. A. Mathot, G. Giaccone, C. A. Punt, H. Rosing, M. X. Hillebrand, Y. Ando, N. 
Nishi, H. Tanaka, J. M. Schellens, and J. H. Beijnen. 2002. Population pharmacokinetics of 
the novel anticancer agent KRN7000. Cancer Chemother Pharmacol 49:287. 
 
137. Motohashi, S., K. Nagato, N. Kunii, H. Yamamoto, K. Yamasaki, K. Okita, H. Hanaoka, N. 
Shimizu, M. Suzuki, I. Yoshino, M. Taniguchi, T. Fujisawa, and T. Nakayama. 2009. A 
phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral 
blood mononuclear cells in patients with advanced and recurrent non-small cell lung 
cancer. J Immunol 182:2492. 
 
138. Van Kaer, L. 2004. Regulation of immune responses by CD1d-restricted natural killer T 
cells. Immunol Res 30:139. 
 
139. Yu, K. O., and S. A. Porcelli. 2005. The diverse functions of CD1d-restricted NKT cells and 
their potential for immunotherapy. Immunol Lett 100:42. 
 
140. Grubor-Bauk, B., A. Simmons, G. Mayrhofer, and P. G. Speck. 2003. Impaired clearance 
of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the 
semivariant V alpha 14-J alpha 281 TCR. J Immunol 170:1430. 
 
141. Taniguchi, M., T. Tashiro, N. Dashtsoodol, N. Hongo, and H. Watarai. The specialized 
iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired 
immune systems with potential applications for cancer therapy. Int Immunol 22:1. 
 
142. Van Kaer, L. 2004. Natural killer T cells as targets for immunotherapy of autoimmune 
diseases. Immunol Cell Biol 82:315. 
 
143. Grunfeld, C. Dyslipidemia and its Treatment in HIV Infection. Top HIV Med 18:112. 
 
